<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0"><channel><title>Media RSS Feed</title><link>https://www.cooley.com/corporate-content/rss-feeds/media-rss-feed</link><description>All Media &amp; Insights RSS Feed</description><language>en</language><ttl>60</ttl><item><guid isPermaLink="false">{8D96AF1C-F871-4023-B467-E8E23D0B2194}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-10-avere-therapeutics-announces-$500-million-private-placement</link><title>Avere Therapeutics Announces $500 Million Private Placement</title><description>&lt;p&gt;&lt;strong&gt;San Francisco &amp;ndash; August 10, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised Jefferies, TD Cowen, Evercore ISI, UBS Investment Bank and Wedbush &amp;amp; Co., LLC as the placement agents to Avere Therapeutics, a privately held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, in connection with a &lt;a rel="noopener noreferrer" href="https://www.prnewswire.com/news-releases/avere-therapeutics-announces-500-million-private-placement-to-support-development-of-once-weekly-oral-il-23-therapy-avr-001-302846694.html" target="_blank"&gt;$500 million private placement&lt;/a&gt; from a syndicate of leading healthcare investors. Participants in the private placement included Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors and other institutional investors.&lt;/p&gt;
&lt;p&gt;The private placement is in addition to the previously announced $320 million concurrent private investment, and the combined proceeds will support the continued development of Avere's lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.&lt;/p&gt;
&lt;p&gt;Partners Denny Won, Charlie Kim and Div Gupta led the Cooley team advising the placement agents.&lt;/p&gt;
&lt;p&gt;Cooley previously advised Jefferies and Wedbush &amp;amp; Co., LLC as the placement agents to Avere in connection with &lt;a href="https://www.cooley.com/news/coverage/2026/2026-07-14-avere-therapeutics-announces-merger-agreement-with-nextcure"&gt;a $320 million private investment concurrent with its merger with NextCure in July 2026&lt;/a&gt;.&lt;/p&gt;</description><pubDate>Mon, 10 Aug 2026 18:06:08 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{225386C6-4E4E-47D3-A967-F27843E1D455}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-10-sobi-and-innate-pharma-license-lacutamab-in-t-cell-lymphoma</link><title>Sobi and Innate Pharma License Lacutamab in T-Cell Lymphoma</title><description>&lt;p&gt;&lt;strong&gt;London &amp;ndash; August 10, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised Swedish Orphan Biovitrum AB (publ) (Sobi&amp;reg;) on &lt;a rel="noopener noreferrer" href="https://www.prnewswire.com/news-releases/sobi-enters-strategic-partnership-with-innate-pharma-to-license-lacutamab-in-t-cell-lymphoma-302846936.html" target="_blank"&gt;its strategic partnership with Innate Pharma SA&lt;/a&gt; (Euronext Paris: IPH; Nasdaq: IPHA) (Innate) to enable initiation of the TELLOMAK-3 confirmatory phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S&amp;eacute;zary syndrome, a subtype of CTCL.&lt;/p&gt;
&lt;p&gt;Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S&amp;eacute;zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S&amp;eacute;zary syndrome and mycosis fungoides. Sobi will receive exclusive global rights to commercialise lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive phase 3 results. Closing of the transaction is subject to closing conditions, including the receipt of transaction related anti-trust clearance.&lt;/p&gt;
&lt;p&gt;Lawyers Frances Stocks Allen and Michael Fernando led the Cooley team advising Sobi.&lt;/p&gt;</description><pubDate>Mon, 10 Aug 2026 17:35:51 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{7F5ADD82-9922-49FB-BD32-D26BA5AC127C}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-10-latigo-biotherapeutics-announces-upsized-$345-6-million-ipo</link><title>Latigo Biotherapeutics Announces Upsized $345.6 Million IPO</title><description>&lt;p&gt;&lt;strong&gt;San Diego &amp;ndash; August 10, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised Latigo Biotherapeutics, a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, on &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/08/07/3340893/0/en/latigo-biotherapeutics-announces-pricing-of-upsized-345-6-million-initial-public-offering.html" target="_blank"&gt;its upsized $345.6 million initial public offering&lt;/a&gt; (IPO). Latigo Biotherapeutics&amp;rsquo; common stock began trading on the Nasdaq Global Select Market on August 7, 2026, under the ticker symbol LTGO.&lt;/p&gt;
&lt;p&gt;Lawyers Charles Bair, Grady Chang and Dylan Kornbluth led the Cooley team advising Latigo Biotherapeutics.&lt;/p&gt;</description><pubDate>Mon, 10 Aug 2026 15:30:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{849F62B0-3D1F-4668-8DD5-0E1D64E71AE4}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-10-actio-biosciences-to-be-acquired-by-jazz-pharmaceuticals-for-up-to-$1-32-billion</link><title>Actio Biosciences to Be Acquired by Jazz Pharmaceuticals for Up to $1.32 Billion</title><description>&lt;p&gt;Cooley advised Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel small molecule precision medicines, on its agreement to be acquired by Jazz Pharmaceuticals for $820 million upfront payment and up to $500 million in potential approval and sales milestones. As part of the transaction, and concurrently with closing, Actio Biosciences will spin out a new privately-held entity with certain management, employees and assets (not including ABS-1230 which remains with Actio Biosciences and is being acquired by Jazz).&lt;/p&gt;
&lt;p&gt;The transaction was announced publicly in the following press release, which can be viewed&amp;nbsp;&lt;a rel="noopener noreferrer" href="https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-acquire-actio-biosciences-expanding-rare" target="_blank"&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Bill Roegge, Jamie Leigh, Marc Recht and Carlos Ramirez led the Cooley team advising Actio Biosciences.&lt;/p&gt;
&lt;p&gt;Christophe Beauduin, Mark Windfeld-Hanson, David Burns, Ariane&amp;nbsp;Andrade, Sarah O&amp;rsquo;Gorman, Patrick Reed, Matt Choy, Navya Dasari, David Dalton, Michael Egan, Todd Gluth, Daniel Knauss, Lauren Leonard, Mika Mayer, John Paul Oleksiuk, Sanjay Reddy, Chad Shear, Rubin Waranch, and Joanna Zhang provided invaluable support.&lt;/p&gt;
&lt;p&gt;Cooley previously advised Actio Biosciences on its $55 million Series A (2023) and $66 million Series B (2025).&lt;/p&gt;</description><pubDate>Mon, 10 Aug 2026 15:26:36 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{5BC9C60B-0E4F-4818-8D26-D56DA0FFB52C}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-10-blossomhill-therapeutics-announces-upsized-$150-million-ipo</link><title>BlossomHill Therapeutics Announces Upsized $150 Million IPO</title><description>&lt;p&gt;&lt;strong&gt;San Diego &amp;ndash; August 10, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised BlossomHill Therapeutics, a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, on &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/08/07/3340894/0/en/blossomhill-therapeutics-announces-pricing-of-upsized-150-million-initial-public-offering.html" target="_blank"&gt;its upsized $150 million initial public offering&lt;/a&gt; (IPO). BlossomHill Therapeutics&amp;rsquo; common stock began trading on the Nasdaq Global Select Market on August 7, 2026, under the ticker symbol BLSM.&lt;/p&gt;
&lt;p&gt;Lawyers Ken Rollins, Charlie Kim, Edmond Lay and Dylan Kornbluth led the Cooley team advising BlossomHill Therapeutics.&lt;/p&gt;</description><pubDate>Mon, 10 Aug 2026 15:00:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{CAF22076-1CA9-4F3F-B8B7-094CFBA31157}</guid><link>https://www.cooley.com/news/insight/2026/2026-08-10-fcc-adopts-rules-overhauling-space-station-licensing-rules</link><title>FCC Adopts Rules Overhauling Space Station Licensing Rules</title><description>&lt;p&gt;The Federal Communications Commission (FCC) adopted a &lt;a rel="noopener noreferrer" href="https://docs.fcc.gov/public/attachments/FCC-26-47A1.pdf" target="_blank"&gt;Report and Order and Further Notice of Proposed Rulemaking&lt;/a&gt; on July 22 overhauling its space and earth station licensing framework. The rules aim to provide entities with a more efficient, predictable and flexible process to support commercial deployment of space infrastructure.&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;Updated licensing framework&lt;/h3&gt;
&lt;p&gt;The FCC establishes a &amp;ldquo;licensing assembly line&amp;rdquo; to provide space companies a clearer and quicker process for obtaining authorizations. The framework adopts a modularized, certification-based application designed to only collect necessary information and streamline the review and approval process.&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;Removal of surety bond requirements&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;The new rules eliminate the surety bond requirements for all systems, except for non-geostationary orbit (NGSO) systems involved in processing rounds (i.e., fixed satellite service and mobile satellite service systems). For NGSO systems subject to processing rounds, the FCC will require a bond set at an initial amount of $10 million, with the bond amount being reduced based on the percentage of the total authorized satellites deployed.&lt;/p&gt;
&lt;h3&gt;Elimination of streamlined small satellite and small spacecraft rules&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;The FCC eliminates the streamlined small satellite and small spacecraft rules, stating that those processes are no longer necessary. The FCC does not, however, address how it will handle current streamlined small satellite or small spacecraft licenses, or how it intends to calculate annual fees for such licenses moving forward, which historically have been less than 1/20 of the annual fees of other NGSO systems.&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;New &amp;lsquo;variable trajectory space stations&amp;rsquo; licensing category&lt;/h3&gt;
&lt;p&gt;Recognizing the continuous development and use of new space technologies, the FCC creates a new category for space stations that does not readily fit into the traditional NGSO or geostationary orbit (GSO) space station categories. The variable trajectory space stations (VTSS) category is for systems &amp;ldquo;of one or more space stations either operating beyond the geosynchronous orbit or operating without fixed or predictable patterns over the course of its lifetime and operating under one space station call sign.&amp;rdquo; These systems include, but are not limited to, orbital transfer vehicles, rendezvous and proximity operations platforms, in-service servicing systems and missions involving transit to, orbiting of, or operations on the moon or other celestial bodies.&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;Conditional grants&lt;/h3&gt;
&lt;p&gt;Under the new rules, the FCC will issue conditional grants of authorization to further streamline and expedite the licensing process. These conditional grants will allow applicants to move forward with launch and/or certain operations prior to obtaining full authorizations from the FCC. &amp;nbsp;&lt;/p&gt;
&lt;h3&gt;Revised processing rounds&lt;/h3&gt;
&lt;p&gt;The FCC updates its processing-round framework to provide NGSO systems greater predictability. Under the new framework, the FCC will open annual processing rounds and review applications on a rolling basis for each year. The Space Bureau will initially open processing rounds for Ka-, Ku-, V- and Q-bands and then add additional bands.&lt;/p&gt;
&lt;h3&gt;Further notice of proposed rulemaking&lt;/h3&gt;
&lt;p&gt;In addition to adopting new licensing rules, the FCC seeks comments on additional rules and revisions to further modernize its licensing framework to promote deployment of space operations. Some of these proposed rules include creating a new space-based experimental license; allowing currently operating NGSO satellite systems to combine authorized satellites under a single call sign; and permitting space station licensees to change or add radio frequency sensing capabilities through a minor modification or notification process.&lt;/p&gt;
&lt;p&gt;If you are interested in learning more about the rules and their potential impact,&amp;nbsp;&lt;a rel="noopener noreferrer" href="https://cosmicspace.org/ninja-forms/96gcgc/" target="_blank"&gt;please register for a Lunch &amp;amp; Learn panel&lt;/a&gt; on these and related topics on August 13 from 12:00 to 2:00 pm ET, or reach out to one of the Cooley lawyers listed below.&lt;/p&gt;</description><pubDate>Mon, 10 Aug 2026 13:56:23 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{BE43AD46-82FF-4F78-8554-668402C1261B}</guid><link>https://www.cooley.com/news/insight/2026/2026-08-06-structuring-cvc-backed-funds-a-governance-economics-and-regulatory-deep-dive</link><title>Structuring CVC-Backed Funds: A Governance, Economics and Regulatory Deep Dive</title><description>&lt;p&gt;This article is the second in our series on fund structures for corporate venture capital (CVC) sponsors. The &lt;a href="https://www.cooley.com/news/insight/2025/2025-08-12-structuring-co-gp-agreements-in-the-corporate-venture-capital-landscape"&gt;first article in the series&lt;/a&gt; examined the principal models through which a corporate sponsor can collaborate with a fund manager (FM) at the general partner (GP) level. This article builds on that analysis by examining the governance architecture of each approach in greater depth, specifically the allocation of control, economics, liability and regulatory exposure between the corporate sponsor and the FM. These dimensions are among the most consequential and contested aspects of any CVC fund structuring exercise.&lt;/p&gt;
&lt;p&gt;A corporate sponsor seeking to embed governance influence alongside an FM has a range of structural options available to it.&lt;/p&gt;
&lt;p&gt;While other approaches exist, for example, hiring an unrelated investment team, developing an in-house investment management capability or acquiring majority control of an existing GP, this article examines the four structures most commonly encountered in CVC fund formation:&lt;/p&gt;
&lt;ol&gt;
    &lt;li&gt;Minority equity stake and board representation in the GP entity&lt;/li&gt;
    &lt;li&gt;Investment committee representation&lt;/li&gt;
    &lt;li&gt;Contractual rights arrangements&lt;/li&gt;
    &lt;li&gt;Dual/parallel co-GP structure&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;The four structures are presented broadly in order of increasing governance depth, with the co-GP structure representing the most extensive form of engagement. Each structure is discussed in turn below, with analysis of its key commercial terms and the principal advantages and disadvantages from both the CVC&amp;rsquo;s and FM&amp;rsquo;s perspectives. In practice, negotiated arrangements often combine elements from more than one structure to achieve a bespoke balance that reflects the relative bargaining positions and strategic objectives of the parties.&lt;/p&gt;
&lt;h2&gt;1. Minority equity stake and board representation in the GP entity&lt;/h2&gt;
&lt;p&gt;&lt;img alt="" src="-/media/214e0fc9bed343cc936d4563bea955bc.ashx" style="height:351px; width:936px;" /&gt;&lt;/p&gt;
&lt;p&gt;Under this structure, the CVC acquires a minority equity interest in the GP entity, with the FM retaining majority ownership and control. The equity stake is typically accompanied by minority representation on the GP&amp;rsquo;s board of directors, together with a package of protective rights designed to embed the CVC&amp;rsquo;s governance position durably within the constitutional framework of the GP entity itself.&lt;/p&gt;
&lt;h3&gt;Key commercial terms&lt;/h3&gt;
&lt;p&gt;The CVC holds minority equity in the GP, with the FM retaining majority equity and corresponding majority board representation. The CVC receives an agreed upon share of carried interest, typically pro rata to its GP equity stake. Where an investment manager is engaged to provide advisory services to the fund, management fees will typically flow to the investment manager rather than to the GP itself; any CVC participation in management fee economics is accordingly structured for gross or net economics to flow to the CVC, including through a separate fee-sharing arrangement, rather than as a direct entitlement flowing from GP equity. Protective provisions in the GP&amp;rsquo;s constitutional documents confer information rights and veto rights over defined categories of major decisions, including amendments to the limited partnership agreement (LPA) or other fund documents, hiring or termination of key persons, related party transactions, changes to the fee or carry structure, new GP equity issuances or a change of control of the GP, fund dissolution, and material or conflicted investment decisions.&lt;/p&gt;
&lt;p&gt;The CVC&amp;rsquo;s equity position is further protected by the following provisions, and in many cases is complemented by investment committee rights (discussed in greater detail under structure 2 below), which afford the CVC influence over the most consequential investment and portfolio decisions:&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;Preemption rights, a right of first refusal and tagalong rights on any transfer of GP equity by the FM.&lt;/li&gt;
    &lt;li&gt;Anti-dilution protections against future issuances.&lt;/li&gt;
    &lt;li&gt;Key person provisions addressing the consequences of FM principal departures.&lt;/li&gt;
    &lt;li&gt;Noncompete obligations typically imposed on the CVC parent in respect of specified fund verticals.&lt;/li&gt;
    &lt;li&gt;Deadlock resolution mechanisms (customarily a put/call arrangement or a buy-sell &amp;ldquo;shotgun&amp;rdquo; mechanism) to address irreconcilable disagreements between the parties.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3&gt;CVC&amp;rsquo;s perspective&lt;/h3&gt;
&lt;p&gt;From the CVC&amp;rsquo;s perspective, the principal advantages are economic and constitutional. The board seat is embedded within the GP entity&amp;rsquo;s constitutional framework, making it the most insulated form of governance influence across all four structures. It provides board-level visibility into GP operations and fund-level approvals, though it should be noted that the GP board&amp;rsquo;s functions are often limited to constitutional and administrative matters such as board resolutions, fund approvals of expenses and related-party transaction approvals, while strategic direction, market updates and portfolio-level discussion typically take place at the investment management or investment committee level. The participation in carried interest (and, where applicable, management fee economics as described above) delivers a direct share of the fund&amp;rsquo;s economics. Tagalong rights and the right of first refusal protect the CVC&amp;rsquo;s ability to exit the GP equity stake on the same terms as the FM. The CVC&amp;rsquo;s own regulatory position is expected to remain outside the scope of registration requirements under the Investment Advisers Act of 1940 (Advisers Act), subject to the level of the CVC&amp;rsquo;s control and ownership. Note that this analysis reflects the US regulatory position; other jurisdictions may impose different registration, licensing or regulatory requirements on a CVC that acquires a minority equity interest in a GP entity, and local counsel advice should be sought.&lt;/p&gt;
&lt;p&gt;The disadvantages are significant. By acquiring GP equity, the CVC is indirectly subject to Advisers Act fiduciary duties owed to the fund, creating a higher standard and potentially compliance obligations than arises under other structures examined below. Affiliated transactions between the CVC parent and the fund give rise to potential conflicts of interest and, in some cases, principal transaction concerns. GP entity valuation at entry and at any subsequent exit is complex and frequently contentious. If the fund underperforms, disputes over carried interest allocation or the CVC&amp;rsquo;s share of management fee economics may arise between the CVC and the FM, particularly where fee revenues decline and the parties disagree over the apportionment of reduced economics.&lt;/p&gt;
&lt;h3&gt;FM&amp;rsquo;s perspective&lt;/h3&gt;
&lt;p&gt;From the FM&amp;rsquo;s perspective, the CVC&amp;rsquo;s equity commitment provides institutional validation (particularly for first-time or emerging fund sponsors) and working capital for the GP entity, as well as a portion of the GP&amp;rsquo;s commitment to the fund. The deadlock resolution mechanism described above (customarily structured as a put/call arrangement or a buy-sell &amp;ldquo;shotgun&amp;rdquo; mechanism) affords the FM a defined exit pathway from the CVC relationship should the parties&amp;rsquo; interests diverge. The CVC&amp;rsquo;s commercial network and strategic resources may be committed to the fund either through the equity relationship or through separate contractual arrangements, though the equity structure creates a more durable alignment of incentives than informal or purely contractual undertakings.&lt;/p&gt;
&lt;p&gt;The downsides for the FM are also material. The loss of sole control over the GP entity and the dilution of carry and fee economics are significant concessions. The FM must manage a minority shareholder relationship alongside a diverse LP base, adding governance complexity. There is a real risk that the FM is not perceived as an independent and disinterested fiduciary for the capital contributed by other LPs, particularly where the CVC parent has interests in portfolio companies or co-investment opportunities. Veto rights create operational friction and can delay time-sensitive investment decisions. Where the CVC&amp;rsquo;s capital is committed through the GP commitment (as is typical), the risk of most-favored-nation (MFN) claims from other LPs is reduced; however, if the CVC also invests as an LP or receives preferential side letter terms, the obligation to disclose the CVC&amp;rsquo;s preferential treatment may invite MFN claims from existing and prospective LPs unless those rights are expressly carved out of the MFN framework. Further, if the CVC parent undergoes a change of control, this may engage the assignment provisions under the Advisers Act. However, where the CVC is a minority investor in the GP and the FM retains clear majority ownership and control, a change of control of the CVC would not necessarily constitute a change of control of the GP for assignment purposes, though the analysis is fact-specific, and the fund documents should address the consequences of a CVC parent change of control expressly.&lt;/p&gt;
&lt;h2&gt;2. Investment committee representation&lt;/h2&gt;
&lt;p&gt;&lt;img alt="" src="-/media/d68499faba094576a6c8d86167c9a572.ashx" style="height:293px; width:936px;" /&gt;&lt;/p&gt;
&lt;p&gt;Under this structure, the CVC holds minority seats on the fund&amp;rsquo;s investment committee (IC) without acquiring any equity interest in the GP entity. The FM retains full GP ownership and control, as well as majority representation on the IC. The CVC&amp;rsquo;s influence over investment decisions is negotiable, ranging from observer only to effective veto rights related to specified categories of decisions.&lt;/p&gt;
&lt;h3&gt;Key commercial terms&lt;/h3&gt;
&lt;p&gt;The CVC appoints minority IC members, who may sit as voting members or as nonvoting observers depending on the terms negotiated. IC quorum requirements typically mandate the presence of at least one CVC representative (or a waiver) before a quorum is constituted. CVC veto rights could be limited to defined categories of decisions, typically including investments above a specified percentage of fund size, investments in sectors competitive with the CVC parent, follow-on investments above agreed concentration limits, below-cost or related-party exit decisions, and co-investment allocation decisions.&lt;/p&gt;
&lt;p&gt;Mandatory recusal protocols address decisions in which the CVC parent has a conflict of interest. Strict nondisclosure obligations and information barriers between CVC IC members and the CVC parent are essential features to prevent confidential deal intelligence from migrating from the CVC's IC representatives to the CVC parent. IC appointees are removable for cause, and any replacement is subject to the FM&amp;rsquo;s reasonable consent. A fundamental drafting question concerns whether CVC IC members vote in their personal capacity or as agents of the CVC entity. If acting as agents, knowledge acquired by IC representatives may be attributed to the CVC entity directly, broadening potential liability exposure and complicating conflict management and regulatory requirements. Conversely, if acting in a personal capacity, the CVC entity has less formal control over how its nominees exercise their votes, and the enforceability of IC voting instructions may be limited. The answer to this question also affects how confidential information obligations are structured. In addition, the FM and the CVC will need to assess the FM&amp;rsquo;s regulatory requirements resulting from CVC and its employees&amp;rsquo; access to the FM&amp;rsquo;s information and network.&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;CVC&amp;rsquo;s perspective&lt;/h3&gt;
&lt;p&gt;From the CVC&amp;rsquo;s perspective, this structure affords greater access to investment decisions with the potential to influence those decisions. Early visibility into proprietary deal flow in sectors of strategic relevance to the CVC parent is a significant benefit. The regulatory footprint is considerably lighter than under structure 1, and exit from the arrangement is simpler. There is no GP equity interest to unwind. There is, however, a reputational risk to the CVC if its IC representatives are perceived to have blocked or delayed deals. The parties may also negotiate a separate carry arrangement, under which IC representation is accompanied by a defined economic participation in fund profits. It should be noted that carried interest grants are not inherently tied to GP equity ownership; carry allocations may be structured independently of the GP&amp;rsquo;s equity capital structure, and accordingly the economic distinction between a carry arrangement under this structure and the carry entitlement flowing from GP equity under structure 1 may be more a matter of structural form than economic substance.&lt;/p&gt;
&lt;p&gt;The disadvantages are meaningful. CVC IC representatives may be treated as access persons of the investment adviser, with consequent compliance and information-handling obligations. Those requirements could expand to CVC without appropriate information gates. Conflict recusal protocols are operationally complex, and contested recusals create friction with the FM and other LPs. The CVC&amp;rsquo;s veto rights likely should be disclosed to other LPs, and other investor may not want the FM&amp;rsquo;s investment discretion impacted by the CVC. Confidential deal intelligence is necessarily exposed to the CVC&amp;rsquo;s IC representatives, creating a risk that commercially sensitive information migrates to the CVC parent notwithstanding information barriers.&lt;/p&gt;
&lt;h3&gt;FM&amp;rsquo;s perspective&lt;/h3&gt;
&lt;p&gt;From the FM&amp;rsquo;s perspective, this structure preserves full GP equity ownership and economics without necessarily dilution of carry or fee entitlements. The CVC could have a range of influence investment decisions, and veto rights, if any, could be limited to defined categories of decision with the FM retaining majority control of the IC. IC rights can be structured to sunset at the end of the investment period, limiting the duration of the CVC&amp;rsquo;s governance influence.&lt;/p&gt;
&lt;p&gt;The drawbacks are also significant. The CVC&amp;rsquo;s veto may delay or block time-sensitive investment decisions. Confidential deal flow and portfolio data are necessarily exposed to a corporate LP whose parent may compete with portfolio companies, and intelligence may migrate inadvertently to the CVC parent despite information barriers. Other LPs may invoke MFN provisions to demand equivalent observation rights. Deadlock mechanics are required but often contentious to negotiate.&lt;/p&gt;
&lt;h2&gt;3. Contractual rights arrangements&lt;/h2&gt;
&lt;p&gt;&lt;img alt="" src="-/media/14a5ff76b091418c9cf36bd2973915e0.ashx" style="height:329px; width:936px;" /&gt;&lt;/p&gt;
&lt;p&gt;Under this structure, the CVC and FM enter into a suite of stand-alone contractual arrangements that confer defined management-adjacent rights on the CVC, without any equity stake in the GP or formal seat on any governance body. This is the lightest-touch governance structure of the four and affords the greatest flexibility to both parties.&lt;/p&gt;
&lt;h3&gt;Key commercial terms&lt;/h3&gt;
&lt;p&gt;The contractual arrangements typically comprise some or all of the following elements:&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;&lt;strong&gt;Co-investment rights.&lt;/strong&gt; A right for the CVC (or its parent) to participate alongside the fund in portfolio investments on a pro rata or fixed-allocation basis, on no-fee, no-carry or preferential terms.&lt;/li&gt;
    &lt;li&gt;&lt;strong&gt;Deal sourcing exclusivity window.&lt;/strong&gt; A contractual obligation on the FM to present defined categories of investment opportunity to the fund (rather than to competing vehicles) for a specified period before the FM may pursue them elsewhere.&lt;/li&gt;
    &lt;li&gt;&lt;strong&gt;Enhanced information rights.&lt;/strong&gt; Reporting rights beyond those available to ordinary LPs, including access to deal pipeline data, portfolio company information and IC materials relevant to the CVC parent&amp;rsquo;s sectors of strategic interest.&lt;/li&gt;
    &lt;li&gt;&lt;strong&gt;Portfolio assistance framework.&lt;/strong&gt; A services or secondment arrangement under which the CVC parent provides defined resources &amp;ndash; commercial, technical or operational &amp;ndash; to portfolio companies, typically on arm&amp;rsquo;s-length terms.&lt;/li&gt;
    &lt;li&gt;&lt;strong&gt;Advisory or observer rights.&lt;/strong&gt; A right for the CVC to appoint a nonvoting observer to the IC or the GP&amp;rsquo;s board, without any veto or quorum right, to preserve visibility into fund governance without triggering the regulatory or fiduciary consequences of formal membership.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3&gt;CVC&amp;rsquo;s perspective&lt;/h3&gt;
&lt;p&gt;From the CVC&amp;rsquo;s perspective, this structure carries the lightest regulatory footprint of the four; the CVC&amp;rsquo;s rights are contractual as in option 2 and are less likely to give rise to regulatory obligations associated with GP or IC status. Each right can be negotiated, transferred or terminated independently of the others, providing maximum flexibility as the CVC-FM relationship evolves. In many cases, co-investment rights can deliver direct and immediate financial value. The portfolio assistance framework directly serves the CVC parent&amp;rsquo;s corporate development agenda without requiring formal governance involvement.&lt;/p&gt;
&lt;p&gt;The disadvantages lie principally in enforcement and durability. While all of the structures examined in this article are contractual in nature, the distinction here is one of structural resilience: Rights embedded in the GP&amp;rsquo;s constitutional documents benefit from the procedural protections and amendment thresholds applicable to those instruments, whereas stand-alone agreements may be more readily amended, waived or terminated by the parties, which may not provide timely protection in a fast-moving investment context. The deal sourcing exclusivity window can constrain the pace of both the fund and the CVC parent. All rights must be carefully drafted to ensure they survive any assignment or novation of the investment management agreement between the FM and a successor investment manager, so that the CVC&amp;rsquo;s entitlements are preserved in the event of a change in the identity of the party providing investment management services to the fund. A CVC that exercises its contractual rights with sufficient regularity and depth risks being characterized as a de facto fund manager, with associated liability consequences.&lt;/p&gt;
&lt;h3&gt;FM&amp;rsquo;s perspective&lt;/h3&gt;
&lt;p&gt;From the FM&amp;rsquo;s perspective, this structure is the least disruptive to its ownership, control and economics. Full GP ownership is retained, and the flexibility of independent contractual arrangements allows each right to be negotiated, modified or terminated without affecting the others. The strategic advisory relationship can enhance the LP value proposition at low governance cost to the FM.&lt;/p&gt;
&lt;p&gt;The principal downsides for the FM relate to the ripple effects on its other LP relationships. Co-investment terms and enhanced information rights will frequently trigger MFN demands from other LPs. The deal sourcing exclusivity window can constrain the pace of deal execution for the fund as a whole. Multiple separate agreements create operational complexity and a risk of inconsistency between documents. Portfolio assistance arrangements must be structured on strictly arm&amp;rsquo;s-length terms to avoid self-dealing claims from other LPs. The FM will also need to assess its compliance obligations, disclosures to other investors and how the relationships fit within the FM&amp;rsquo;s compliance policies and procedures.&amp;nbsp;&lt;/p&gt;
&lt;h2&gt;4. Dual/parallel co-GP structure&lt;/h2&gt;
&lt;p&gt;&lt;img alt="" src="-/media/2603e2496e8b443ba939b6d015cab190.ashx" style="height:339px; width:936px;" /&gt;&lt;/p&gt;
&lt;p&gt;The co-GP structure is the most ambitious and operationally complex of the four. Unlike the joint venture model examined in our first article (model 3), which involves shared equity ownership of a single GP entity by the corporate sponsor and an industry partner, this structure involves two separate legal entities, the FM&amp;rsquo;s own GP and a newly established CVC co-GP entity, each named as a GP of the fund in the LPA. Both co-GPs bear joint and several liability to the fund&amp;rsquo;s LPs, and share in the economics of the GP according to an agreed formula. The governance, liability and regulatory issues specific to dual co-GP structures, including inter-GP coordination, separate regulatory obligations and fund continuation mechanics, are examined in detail below.&lt;/p&gt;
&lt;h3&gt;Key commercial terms&lt;/h3&gt;
&lt;p&gt;Both entities are named as co-GPs in the LPA, with carry (and occasionally, management fees as well) allocated between them in accordance with an agreed formula. A co-GP governance agreement sets out with precision the matters that require unanimous consent and those that can be decided by either a co-GP or majority. Unanimous consent matters typically include amendments to the LPA or other fund documents, changes to investment strategy or mandate, investment decisions above a defined threshold, key person appointments and terminations at either co-GP, related party transactions, dissolution of the fund or either GP entity, any assignment of GP rights or management economics, and material changes to compliance or regulatory frameworks.&lt;/p&gt;
&lt;p&gt;While both co-GPs are jointly and severally liable to LPs under the LPA, an internal indemnification agreement allocates liability between the co-GPs. Each co-GP entity independently satisfies its own regulatory obligations, with costs allocated separately. Key persons are defined separately for each co-GP entity. Fund continuation mechanics address the scenario in which one co-GP exits or is removed for cause, permitting the remaining co-GP to continue as sole GP subject to LP consent.&lt;/p&gt;
&lt;h3&gt;CVC&amp;rsquo;s perspective&lt;/h3&gt;
&lt;p&gt;From the CVC&amp;rsquo;s perspective, this structure provides the most formal and equal governance standing of any of the four options. True co-GP status means the CVC is a named GP of the fund in the LPA, placing it on the same constitutional footing as the FM. The CVC obtains direct access to GP economics without acquiring an equity interest in the FM&amp;rsquo;s preexisting GP entity. The structure enables the CVC to build an independent investment management capability alongside the FM, and signals a long-term commitment to the fund, including through a capital commitment made by the CVC co-GP entity (or its affiliate), that may strengthen its fundraising profile with other LPs.&lt;/p&gt;
&lt;p&gt;The disadvantages are commensurately high. GP liability represents a significant balance sheet risk for the CVC&amp;rsquo;s corporate parent. Establishing a CVC co-GP entity could trigger Advisers Act registration and compliance obligations for the CVC and CVC parent. Inter-GP coordination is operationally complex, and the risk of decision gridlock is at its highest in this structure. Advisers Act fiduciary duties are owed to the fund, not merely to the CVC. Any change of control of the CVC co-GP entity, including the CVC parent, will engage complex GP succession mechanics, potentially requiring LP consent.&lt;/p&gt;
&lt;h3&gt;FM&amp;rsquo;s perspective&lt;/h3&gt;
&lt;p&gt;From the FM&amp;rsquo;s perspective, the CVC co-GP enhances the fundraising profile and institutional credibility of the fund. The CVC bears a proportionate share of any GP-level liability, reducing the FM&amp;rsquo;s net exposure. The arrangement provides the FM with access to the CVC&amp;rsquo;s deal flow, commercial networks and LP base.&lt;/p&gt;
&lt;p&gt;The disadvantages are the most severe of any of the four structures. The co-GP arrangement is the most operationally complex option, with the highest risk of decision gridlock. The FM loses its status as sole fund fiduciary, which may undermine its leverage in negotiations with portfolio companies and third parties. The carry pool is materially reduced by the co-GP split. If the CVC co-GP is removed for cause or withdraws, fund continuity mechanics may trigger LP removal rights or necessitate a fund restructuring. Two separately regulated entities significantly increase compliance costs.&lt;/p&gt;
&lt;h2&gt;5. Comparative analysis&lt;/h2&gt;
&lt;p&gt;The four structures can be assessed across five principal dimensions: governance footprint, CVC liability exposure, CVC economics, CVC regulatory risk and the degree of control dilution for the FM. The table below summarizes this comparison.&lt;/p&gt;
&lt;div class="table"&gt;
&lt;table width="100%"&gt;
    &lt;thead&gt;
        &lt;tr&gt;
            &lt;td&gt;
            &lt;p&gt;&lt;strong&gt;Structure&lt;/strong&gt;&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;&lt;strong&gt;Governance footprint&lt;/strong&gt;&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;&lt;strong&gt;CVC liability&lt;/strong&gt;&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;&lt;strong&gt;CVC economic participation&lt;/strong&gt;&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;&lt;strong&gt;CVC regulatory risk&lt;/strong&gt;&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;&lt;strong&gt;FM control dilution&lt;/strong&gt;&lt;/p&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
    &lt;/thead&gt;
    &lt;tbody&gt;
        &lt;tr&gt;
            &lt;td&gt;
            &lt;p&gt;1. Minority GP equity + board&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;High&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Moderate to high&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Pro rata fees and carry&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;High&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Moderate to high&lt;/p&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
            &lt;td&gt;
            &lt;p&gt;2. IC representation&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Moderate&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Low&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;None (separate carry optional)&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Low&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Low&lt;/p&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
            &lt;td&gt;
            &lt;p&gt;3. Contractual arrangements&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Low&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Low&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Co-invest/carry by agreement&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Low&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Low&lt;/p&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
            &lt;td&gt;
            &lt;p&gt;4. Dual co-GP structure&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Highest&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Highest&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Equal to agreed GP split&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Highest&lt;/p&gt;
            &lt;/td&gt;
            &lt;td&gt;
            &lt;p&gt;Highest&lt;/p&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
    &lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;h2&gt;Conclusion&lt;/h2&gt;
&lt;p&gt;The choice between these four structures is ultimately a function of the CVC&amp;rsquo;s strategic objectives, its appetite for liability and regulatory exposure, the FM&amp;rsquo;s willingness to accept governance dilution, and the interests of the wider LP base. A CVC that prioritizes direct economic participation and durable governance influence will gravitate toward structure 1 or structure 4, accepting the associated liability and regulatory complexity. A CVC that seeks strategic insight and deal flow access with a lighter touch will favor structures 2 or 3, preserving flexibility and minimizing regulatory risk.&lt;/p&gt;
&lt;p&gt;It is important to note that these structures are not mutually exclusive. In practice, a negotiated arrangement commonly combines elements from multiple structures &amp;ndash; for example, IC representation paired with a suite of contractual rights, or a minority GP equity stake accompanied by a co-investment framework. The most successful arrangements are those that are clearly documented, anticipate the principal friction points (conflicts, key person departures, deadlock and LP scrutiny), and build in mechanisms to resolve them without resorting to litigation.&lt;/p&gt;
&lt;p&gt;As corporate venture capital continues to mature as an asset class, the governance architecture of CVC-backed funds will remain a focal point for legal advisors, fund managers and institutional LPs alike. Structuring these arrangements carefully at the outset, with clear eyes about the trade-offs involved, is essential to the long-term health of the fund and the CVC-FM relationship.&lt;/p&gt;</description><pubDate>Thu, 06 Aug 2026 11:04:42 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{7D8DF969-46F0-4C9F-ADD9-E671B9489954}</guid><link>https://www.cooley.com/news/insight/2026/2026-08-06-ninth-circuit-rules-on-ai-agent-access-to-third-party-websites-under-cfaa</link><title>Ninth Circuit Rules on AI Agent ‘Access’ to Third-Party Websites Under CFAA</title><description>&lt;p&gt;On August 4, 2026, the US Court of Appeals for the Ninth Circuit vacated a preliminary injunction that had barred Perplexity&amp;rsquo;s AI agent from accessing Amazon.com on customers&amp;rsquo; behalf, holding that Amazon was unlikely to succeed on its Computer Fraud and Abuse Act (CFAA) and California Comprehensive Computer Data Access and Fraud Act (CDAFA) claims against Perplexity. Reversing the district court, the panel explained that when a user tasks a Perplexity agent with taking actions on the user&amp;rsquo;s behalf on Amazon.com, it is &amp;ldquo;the user who &amp;lsquo;accessed&amp;rsquo; Amazon&amp;rsquo;s computers,&amp;rdquo; not Perplexity. The decision is significant for both sides of the agentic AI ecosystem: It potentially offers AI developers a measure of protection from CFAA/CDAFA claims arising from agents acting at a user&amp;rsquo;s direction, while signaling to website operators that these anti-hacking statutes may not be an effective tool for policing agent access &amp;ndash; though other legal theories, such as breach of terms of service, may remain available.&lt;/p&gt;
&lt;p&gt;Two important limits temper the decision for both audiences. First, the ruling addresses only CFAA and CDAFA theories of liability and expressly leaves open other claims, including breach of terms of service and contract- or tort-based theories. Second, the panel made clear that the inquiry is fact-specific, noting the possibility that other AI agents with greater autonomy or more direct communication with a website&amp;rsquo;s servers could still give rise to CFAA and CDAFA liability. Because this appeal arose from a preliminary injunction, the panel&amp;rsquo;s findings reflect a likelihood-of-success assessment on the current record, not a final merits ruling.&lt;/p&gt;
&lt;h3&gt;Background&lt;/h3&gt;
&lt;p&gt;Amazon sued Perplexity in the US District Couty Northern District of California, alleging that Perplexity&amp;rsquo;s agentic browser feature, the &amp;ldquo;Assistant&amp;rdquo; (part of its Comet browser), accessed Amazon users&amp;rsquo; password-protected Amazon accounts to browse and purchase products &amp;ndash; at users&amp;rsquo; direction. Amazon alleged that Assistant did so without identifying itself to Amazon as an AI agent and in violation of Amazon&amp;rsquo;s terms of service. Amazon claimed this conduct violated the federal CFAA and CDAFA. On March 9, 2026, &lt;a href="~/link.aspx?_id=9E78E39A5AF54EEB881959BCBD71CED9&amp;amp;_z=z"&gt;the district court granted Amazon&amp;rsquo;s preliminary injunction&lt;/a&gt;, finding Amazon was likely to succeed on the merits because Perplexity&amp;rsquo;s access was not authorized by Amazon, regardless of whether the Amazon users had permitted Assistant to access their own Amazon accounts. Perplexity appealed.&lt;/p&gt;
&lt;h3&gt;The Ninth Circuit&amp;rsquo;s decision&lt;/h3&gt;
&lt;p&gt;On August 4, 2026, a Ninth Circuit panel vacated the injunction and remanded the case for further proceedings.&lt;/p&gt;
&lt;p&gt;The panel&amp;rsquo;s decision turned on the threshold question of computer &amp;ldquo;access&amp;rdquo; under the CFAA. To prevail on a CFAA claim, a plaintiff must show that the defendant:&lt;/p&gt;
&lt;ol&gt;
    &lt;li&gt;Intentionally accessed a computer&lt;/li&gt;
    &lt;li&gt;Without authorization or in excess of authorized access&lt;/li&gt;
    &lt;li&gt;Thereby obtaining information&lt;/li&gt;
    &lt;li&gt;From a protected computer&lt;/li&gt;
    &lt;li&gt;Causing at least $5,000 in aggregate loss in a one-year period&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;The court found that &amp;ldquo;access&amp;rdquo; means &amp;ldquo;entering a computer system itself,&amp;rdquo; and the statute&amp;rsquo;s use of &amp;ldquo;whoever&amp;rdquo; contemplates access by a person, not a software tool. As a result, &amp;ldquo;it was the user who &amp;lsquo;accessed&amp;rsquo; Amazon&amp;rsquo;s computers, with the help of Perplexity&amp;rsquo;s AI agent, the &amp;lsquo;Assistant,&amp;rsquo; to carry out specific acts on Amazon.com.&amp;rdquo; Because the user, not Perplexity, accessed Amazon&amp;rsquo;s servers, the court found Amazon was unlikely to prevail on a CFAA claim against Perplexity.  &lt;/p&gt;
&lt;p&gt;To reach this holding, the court examined how Assistant works. When a user directs the Assistant to shop on Amazon, the Assistant takes screenshots of the browser view on the user&amp;rsquo;s own machine and sends those screenshots to Perplexity&amp;rsquo;s servers, which then send back instructions on how to navigate Amazon.com to the user&amp;rsquo;s computer. Critically, &amp;ldquo;Perplexity itself does not directly communicate with Amazon&amp;rsquo;s servers,&amp;rdquo; as communications are routed through the user&amp;rsquo;s computer. The court distinguished this fact pattern from those in cases such as &lt;em&gt;Facebook, Inc. v. Power Ventures, Inc.&lt;/em&gt;, where the defendant&amp;rsquo;s own systems caused messages to be transmitted directly on Facebook&amp;rsquo;s platform, without first passing through a user&amp;rsquo;s machine. &lt;/p&gt;
&lt;p&gt;The CDAFA was likely to fail for the same reason. Although the CDAFA defines &amp;ldquo;access&amp;rdquo; more broadly than the CFAA, the panel held that the statute still focuses on the person accessing or causing access. Because the user, not Perplexity, accessed Amazon&amp;rsquo;s systems, Amazon&amp;rsquo;s CDAFA claim was also unlikely to succeed.&lt;/p&gt;
&lt;p&gt;Finally, the court also held that the equitable factors underlying a preliminary injunction favored Perplexity, as Amazon&amp;rsquo;s evidence of irreparable harm &amp;ndash; claims that the Assistant might not select the best price or product for a user &amp;ndash; was comparatively weak and abstract, and that Amazon&amp;rsquo;s cybersecurity concerns were unconvincing. &lt;/p&gt;
&lt;h3&gt;Remaining liability risk&lt;/h3&gt;
&lt;p&gt;The court made clear that different facts regarding how the agent operated may have changed the outcome.  For example, if an AI company exercises greater control over its agent or if the company&amp;rsquo;s servers communicated directly with the defendant&amp;rsquo;s servers, that may yet support a finding that the company itself &amp;ldquo;accessed&amp;rdquo; a website&amp;rsquo;s servers. &lt;/p&gt;
&lt;p&gt;The court also expressly narrowed the holding to the CFAA and CDAFA contexts. The court left open the possibility that the same conduct could be the basis for other types of claims, such as claims sounding in tort or contract. &lt;/p&gt;
&lt;h3&gt;Practical takeaways for website operators&lt;/h3&gt;
&lt;p&gt;Websites seeking to restrict AI agents from accessing accounts or taking actions on a user&amp;rsquo;s behalf should not assume that the CFAA or similar state anti-hacking statutes will provide an effective remedy, at least where the AI company&amp;rsquo;s own systems do not directly communicate with the website&amp;rsquo;s servers. Such websites may have to turn to other theories of liability, such as enforcing terms of service. &lt;/p&gt;
&lt;h3&gt;Practical takeaways for AI agent developers&lt;/h3&gt;
&lt;p&gt;Makers of agentic AI tools should take some comfort from the Ninth Circuit&amp;rsquo;s finding that a user directing an AI agent &amp;ndash; rather than the AI company itself &amp;ndash; is the one who &amp;ldquo;accesses&amp;rdquo; a third-party website for CFAA and CDAFA purposes, at least where communications with the third-party website&amp;rsquo;s servers are routed through the user&amp;rsquo;s computer. This finding puts new emphasis on how the AI agent communicates; agents that do not rely on the user&amp;rsquo;s computer as a relay will pose greater risk. AI developers should not treat this decision as foreclosing liability under other legal theories, including contract-based claims arising from a website&amp;rsquo;s terms of service.&lt;/p&gt;</description><pubDate>Thu, 06 Aug 2026 07:00:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{C66B8C19-5FF6-4D0B-8A26-2425D1D5D7CA}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-05-nn-inc-announces-$124-million-refinancing-and-deleveraging-transaction</link><title>NN, INC. Announces $124 Million Refinancing and Deleveraging Transaction</title><description>&lt;p&gt;&lt;strong&gt;Chicago &amp;ndash; August 5, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, on its &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/08/05/3339749/0/en/nn-inc-announces-124-million-refinancing-and-deleveraging-transaction.html?_gl=1*zhhnq4*_up*MQ..*_ga*OTg0MDM5NjUuMTc4NTk2NTE5NQ..*_ga_B6167QB2TF*czE3ODU5NjUxOTUkbzEkZzAkdDE3ODU5NjUxOTUkajYwJGwwJGgxODE0OTI4MDgy*_ga_ERWPGTJ5X8*czE3ODU5NjUxOTUkbzEkZzAkdDE3ODU5NjUxOTUkajYwJGwwJGgw" target="_blank"&gt;negotiated transaction regarding the Company&amp;rsquo;s $124 million of Series D preferred stock security&lt;/a&gt; held by investment funds managed by Morgan Stanley Tactical Value.&lt;/p&gt;
&lt;p&gt;Cooley advised NN on financing transactions that resulted in the redemption, exchange and refinancing of its preferred equity securities. The transactions included a $75 million common stock PIPE financing that closed in July 2026, the proceeds of which were used to redeem $70 million of NN&amp;rsquo;s existing Series D preferred stock; the exchange of approximately $19 million of Series D preferred stock for common stock with Morgan Stanley Tactical Value; and the refinancing of the remaining $35 million of Series D preferred stock at a reduced 10% interest rate for one year. The refinancing also provides NN with a $5 million discount if the remaining Series D preferred stock is redeemed by December 31, 2026.&lt;/p&gt;
&lt;p&gt;Lawyers Christina Roupas, Courtney Tygesson, Sam Paullin, Emma Frerichs and Victoria Peluso led the Cooley team advising NN.&lt;/p&gt;
&lt;p&gt;Cooley previously advised NN on its &lt;a href="https://www.cooley.com/news/coverage/2026/2026-01-20-cooley-advises-nn-on-cooperation-agreement-with-legion-partners"&gt;cooperation agreement with Legion Partners&lt;/a&gt; in January 2026.&lt;/p&gt;</description><pubDate>Wed, 05 Aug 2026 16:36:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{1476C858-39C2-49FB-AC29-11905D26A3C1}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-05-expedition-therapeutics-announces-oversubscribed-$115-million-series-b</link><title>Expedition Therapeutics Announces Oversubscribed $115 Million Series B</title><description>&lt;p&gt;&lt;strong&gt;San Diego &amp;ndash; August 5, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, on &lt;a rel="noopener noreferrer" href="https://expeditiontx.com/news/expedition-therapeutics-announces-oversubscribed-115-million-series-b-financing-to-advance-next-generation-dpp1-inhibitor-for-copd/" target="_blank"&gt;the closing of an oversubscribed $115 million Series B financing&lt;/a&gt;. The financing was led by General Atlantic, a leading global investor, with participation from RA Capital and Vivo Capital and existing investors Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma, Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners and Venrock Healthcare Capital Partners.&lt;/p&gt;
&lt;p&gt;Partners Patrick Loofbourrow and Allison Pang led the Cooley team advising Expedition.&lt;/p&gt;</description><pubDate>Wed, 05 Aug 2026 16:30:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{8F41EA85-E2D3-4206-85A5-B02C76DC6DEF}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-05-cooley-lawyers-recognized-as-singapore-rising-stars</link><title>Cooley Lawyers Recognized as Singapore Rising Stars</title><description>&lt;p&gt;Cooley counsel Steven Holm and special counsel Zhijing Yu were recognized by Asian Legal Business as Singapore Rising Stars for 2026. The list spotlights Singapore&amp;rsquo;s emerging legal talent for their technical skill and helping to define what it means to lead in this field &amp;mdash; setting a new benchmark where legal leadership combines deep expertise with the foresight to anticipate and shape what clients need.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.legalbusinessonline.com/features/rankings-alb-singapore-rising-stars-2026" target="_blank"&gt;See the full list of winners&lt;/a&gt;&lt;/p&gt;</description><pubDate>Wed, 05 Aug 2026 16:24:45 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{3FD9C6B8-4692-4C59-A722-095D4189A1E0}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-05-south-park-commons-raises-$575-million-fund-iv</link><title>South Park Commons Raises $575 Million Fund IV</title><description>&lt;p&gt;&lt;strong&gt;San Francisco &amp;ndash; August 5, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised South Park Commons (SPC), a community of technologists and builders, on its &lt;a rel="noopener noreferrer" href="https://www.southparkcommons.com/news/announcing-spc-575m-fund-iv/" target="_blank"&gt;raise of $575 million for SPC Fund IV&lt;/a&gt;, bringing SPC to $2 billion in assets under management.&lt;/p&gt;
&lt;p&gt;Lawyers John Dado, Katia MacNeill, Emily Hren and Maya Nelle Kuchan led the Cooley team advising SPC.&lt;/p&gt;</description><pubDate>Wed, 05 Aug 2026 15:56:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{CA87DBB3-F298-4BDA-ADE9-ABE6682D3972}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-04-three-cooley-lawyers-recognized-as-law360-rising-stars</link><title>Three Cooley Lawyers Recognized as Law360 Rising Stars</title><description>&lt;p&gt;Cooley lawyers Denny Won, Robert Jacques and Bill Roegge were recognized by Law360 as Rising Stars for capital markets, insurance and life sciences, respectively. Based on the careful review of more than 1,100 submissions, Law360 honored more than 160 attorneys under 40 whose legal accomplishments belie their age.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.law360.com/articles/2500494/law360-names-2026-s-top-attorneys-under-40-" target="_blank"&gt;Read the full list of honorees (subscription required)&lt;/a&gt;&lt;/p&gt;</description><pubDate>Tue, 04 Aug 2026 19:03:34 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{D0D854EA-B122-412C-AA92-BA13EDFEA880}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-04-alixpartners-acquires-artium</link><title>AlixPartners Acquires Artium</title><description>&lt;p&gt;&lt;strong&gt;Washington, DC &amp;ndash; August 4, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised Artium, a leading agentic AI software consulting firm specializing in building and launching enterprise-grade agents for clients, on its &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/08/04/3338729/0/en/alixpartners-acquires-leading-agentic-ai-consulting-firm-artium.html" target="_blank"&gt;acquisition by AlixPartners&lt;/a&gt;, a global consulting firm. Artium will operate as a distinct team within AlixPartners, as Artium by AlixPartners. Artium&amp;rsquo;s capabilities, as a part of AlixPartners, will help open new opportunities to transform businesses and integrate technology in ways that deliver sustainable performance improvements across the enterprise.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Lawyers Josh Holleman, Eddie Sniezek, Josh Himmelstern, Ty Chung and Jonathan Rivinus led the Cooley team advising Artium, with support from Carly Mitchell, Scott McCall, Kevin Cooper, Eileen Leman, Nathaniel Hearn, Cristina DeBiase, Parth Bhatt and Morgan Perna.&lt;/p&gt;</description><pubDate>Tue, 04 Aug 2026 16:31:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{B1816896-D45F-4C26-A8E6-BEE26A014B29}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-04-procore-technologies-announces-upsized-$950-million-convertible-senior-notes-offering</link><title>Procore Technologies Announces Upsized $950 Million Convertible Senior Notes Offering</title><description>&lt;p&gt;&lt;strong&gt;San Francisco &amp;ndash; August 4, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised Procore Technologies, Inc. (NYSE: PCOR), the leading global provider of construction management software, on its private placement of $950 million aggregate principal amount of convertible senior notes, which includes the exercise in full of the initial purchasers&amp;rsquo; options to purchase an additional $125 million principal amount of notes.&lt;/p&gt;
&lt;p&gt;Lawyers Logan Tiari, Mischi a Marca, Jason Savich, Jon Avina, Shimeng Cheng, Mollie Yeh, Matthew Scarano, Matt Kong, Victoria Comesanas, Yoni Horn, Timothy Shapiro and Eileen Marshall led the Cooley team advising Procore.&lt;/p&gt;
&lt;p&gt;Cooley previously advised Procore Technologies on its agreement to acquire DroneDeploy in July 2026, its $697.5 million initial public offering in May 2021 and its acquisition of Honest Buildings in July 2019.&lt;/p&gt;</description><pubDate>Tue, 04 Aug 2026 16:00:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{7805C7D7-EE1B-4137-88BB-14506C679C09}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-04-attovia-announces-upsized-$289-million-ipo</link><title>Attovia Announces Upsized $289 Million IPO</title><description>&lt;p&gt;&lt;strong&gt;San Diego &amp;ndash; August 4, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised the underwriters of Attovia Therapeutics, a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, in connection with &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/08/05/3338994/0/en/attovia-therapeutics-announces-pricing-of-upsized-initial-public-offering.html" target="_blank"&gt;Attovia&amp;rsquo;s upsized $289 million initial public offering&lt;/a&gt; (IPO). Attovia issued 17,000,000 shares of its common stock priced at $17 per share, with a 30-day option for the underwriters to purchase 2,550,000 additional shares. Attovia&amp;rsquo;s common stock will begin trading on the Nasdaq Global Market on August 5, 2026, under the ticker symbol ATTO.&lt;/p&gt;
&lt;p&gt;Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital is acting as a passive book-running manager for the offering.&lt;/p&gt;
&lt;p&gt;Partners Charlie Kim, Kristin VanderPas, Denny Won and David Peinsipp and associates David Kim, Jesse Schulman and Joanna Zhang led the Cooley team advising the underwriters.&lt;/p&gt;</description><pubDate>Tue, 04 Aug 2026 15:12:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{AB6A9BC1-063D-4089-916D-2B01DF485DAB}</guid><link>https://www.cooley.com/news/insight/2026/2026-08-04-the-eu-21st-russian-sanctions-package-is-here-business-implications</link><title>The EU 21st Russian Sanctions Package Is Here: Business Implications</title><description>&lt;p&gt;On 23 July 2026, the Council of the European Union adopted the 21st package of sanctions measures against Russia. This package builds on the EU&amp;rsquo;s 20th package of sanctions which was adopted three months ago on 23 April 2026.&lt;/p&gt;
&lt;p&gt;The measures focus on energy, financial services and crypto, trade and the Russian military-industrial complex. Additionally, the EU sanctioned 218 new persons (48 individuals and 170 entities), which the Council described as the largest batch of listings in four years.&lt;/p&gt;
&lt;p&gt;We have summarised the most salient measures below.&lt;/p&gt;
&lt;h3&gt;Crypto-asset measures&lt;/h3&gt;
&lt;p&gt;In its 20th Package, the EU introduced extensive restrictions on Russia-related crypto activity, including measures against the A7A5 stablecoin, RUBx, and banned all EU support for the digital ruble. The EU further imposed a total sectoral ban on providers and platforms established in Russia allowing the transfer and exchange of crypto-assets.&lt;/p&gt;
&lt;p&gt;The 21st package introduced three distinct crypto-asset measures:&lt;/p&gt;
&lt;ol&gt;
    &lt;li&gt;&lt;strong&gt;Platform transaction bans.&lt;/strong&gt; The 21st package extends transaction bans with crypto-assets to 14 crypto-related service platforms based in Georgia, Panama, the UAE, the Marshall Islands, Kyrgyzstan and Belarus.&lt;/li&gt;
    &lt;li&gt;&lt;strong&gt;Non-Russian in EU crypto-asset business.&lt;/strong&gt; From 25 August 2026, Russian nationals and people living in Russia cannot:&lt;/li&gt;
&lt;/ol&gt;
&lt;p style="padding-left: 30px;"&gt;i. Own or control (directly or indirectly) a crypto-asset business based in an EU Member State.&lt;/p&gt;
&lt;p style="padding-left: 30px;"&gt;ii. Sit on the board or governing body of such a business.&lt;/p&gt;
&lt;p style="padding-left: 30px;"&gt;This applies to all crypto-asset businesses in the EU.&lt;/p&gt;
&lt;ol start="3"&gt;
    &lt;li&gt;&lt;strong&gt;Country-level ban framework.&lt;/strong&gt; EU persons and entities will be prohibited from transacting, directly or indirectly, with any crypto-asset service provider or exchange platform established in a country that the Council of the EU determines to be undermining Russian sanctions. No country has yet been listed, but this new regulation signals the EU&amp;rsquo;s readiness to impose jurisdiction-level exclusion.&lt;/li&gt;
&lt;/ol&gt;
&lt;h3&gt;Financial measures and asset freezes&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Asset freeze&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;All 218 new designations (48 individuals and 170 entities) are subject to EU asset freezes. This means that their assets must be frozen and EU operators may not make funds or economic resources available to them. The financial sector accounts for the largest share &amp;ndash; 94 banks and major financial institutions including the Moscow Exchange. As part of the 20th package of sanctions, the EU had designated several banks and defence-related companies and individuals and imposed further restrictions on entities in China, Hong Kong, the UAE, T&amp;uuml;rkiye, Kazakhstan, Uzbekistan and Belarus involved in supplying dual-use or military goods to Russia.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Transaction ban&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;The 21st package further expands the transaction-ban framework introduced in earlier packages, to 33 additional Russian credit and financial institutions, one Kyrgyz bank connected to Russia&amp;rsquo;s SPFS system, three other non-Russian banks, and five oil traders that helped circumvent the Russian crude oil prohibition. More than 100 Russian banks are now subject to financial messaging and transaction restrictions in total.&lt;/p&gt;
&lt;h3&gt;Trade measures&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Export bans&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;New restrictions on nickel powders and alloys (jet engine coatings), beryllium powders, self-adhesive films (aerospace and defence), and UAV items, including ground support equipment, jamming and interception systems, launch systems, servomotors and flight termination systems.&lt;/p&gt;
&lt;p&gt; &lt;strong&gt;Import bans&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;New bans worth more than &amp;euro;60 million on copper, nickel, lead and precious-metal ores, unwrought zinc, alkaline-earth metals, zinc and chromium oxides, glassware, imitation pearls and car parts &amp;nbsp;The new import prohibitions do not apply to contracts concluded before 24 July 2026 that are being executed until 25 October 2026.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Entity list&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Fifty-one entities are added to the list of entities subject to stricter export restrictions because of their support for Russia&amp;rsquo;s military and industrial complex and role in circumvention. The newly listed entities include third-country entities in China, India, Kazakhstan, Kyrgyzstan, T&amp;uuml;rkiye and the UAE.&lt;/p&gt;
&lt;h3&gt;Next steps for companies with Russian exposure&lt;/h3&gt;
&lt;p&gt;Businesses with Russian exposure should use the package as a prompt to refresh sanctions screening, counterparty diligence and contract reviews across the areas most affected by the new measure:&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;Screen against new asset freezes&lt;/li&gt;
    &lt;li&gt;Screen against expanded transaction bans&lt;/li&gt;
    &lt;li&gt;Review crypto platform relationships&lt;/li&gt;
    &lt;li&gt;Review existing import contracts &amp;ndash; transition period runs to 25 October 2026 for contracts concluded before 24 July 2026&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;The key point is to identify any exposure early, particularly where the package expands restrictions beyond Russian entities to third-country platforms, vessels, banks and service providers.&lt;/p&gt;</description><pubDate>Tue, 04 Aug 2026 09:46:24 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{67139E03-BE8B-4417-8C1B-593822BD3D75}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-03-are-investment-treaties-the-next-legal-frontier-for-tech-disputes</link><title>Are Investment Treaties the Next Legal Frontier for Tech Disputes?</title><description>&lt;p&gt;Cooley partner Charlie Lightfoot and special counsel Juan Nascimbene co-authored a Global Arbitration Review article, highlighting a new study published jointly by Cooley and the British Institute of International and Comparative Law (BIICL), which explores how international investment arbitration may help technology companies respond to government measures that unfairly affect their foreign investments.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://globalarbitrationreview.com/article/are-investment-treaties-the-next-legal-frontier-tech-disputes" target="_blank"&gt;Read the article (subscription required)&lt;/a&gt;&lt;/p&gt;</description><pubDate>Mon, 03 Aug 2026 20:48:45 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{DE8CD337-0EFC-4CBE-822D-2FD01D79BDD1}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-03-olix-raises-$312-million-at-a-$3-3-billion-valuation</link><title>OLIX Raises $312 Million at a $3.3 Billion Valuation</title><description>&lt;p&gt;&lt;strong&gt;London &amp;ndash; August 3, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised OLIX, a company building the infrastructure for frontier AI inference, on its &lt;a rel="noopener noreferrer" href="https://olix.com/news/company-raises-series-b" target="_blank"&gt;$312 million Series B financing round at a $3.3 billion valuation&lt;/a&gt;, two years after it was founded.&lt;/p&gt;
&lt;p&gt;The round included Fundomo, Arm and Hudson River Trading, alongside angel investors including Reed Hastings, the co-founder of Netflix, with existing investors Hummingbird Ventures, Crane, Plural, Creandum, Phoenix Court and Transition all increasing their commitments.&lt;/p&gt;
&lt;p&gt;Lawyers Ali Ramadan, Charles Baker, Mo Swart, Christopher Kimball, Juan Nascimbene and Karen Tsai led the Cooley team advising OLIX.&lt;/p&gt;
&lt;p&gt;Cooley previously advised OLIX on its &lt;a href="https://www.cooley.com/news/coverage/2026/2026-02-11-olix-raises-$220-million-in-financing"&gt;$220 million financing round&lt;/a&gt; in February 2026.&lt;/p&gt;</description><pubDate>Mon, 03 Aug 2026 19:16:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{F2A47A02-55B4-4DA5-9685-535FB85D0EAB}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-03-ais-cookie-banner-moment-eu-labels-come-for-the-bots</link><title>AI’s ‘Cookie Banner’ Moment: EU Labels Come for the Bots</title><description>&lt;p&gt;Cooley partner Patrick Van Eecke was quoted in a Financial Times article about European companies preparing to comply with the first consumer-facing transparency requirements under the EU AI Act, noting that until now the AI Act has largely felt abstract, but consumers will begin seeing labels identifying AI-generated content.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.ft.com/content/19ff059b-1d02-4f0e-9b34-ce96edb0cb13?syn-25a6b1a6=1" target="_blank"&gt;Read the article (subscription required)&lt;/a&gt;&lt;/p&gt;</description><pubDate>Mon, 03 Aug 2026 19:13:53 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{E95CA97F-BC91-4091-8507-CFAF0D3CB49A}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-03-autolus-therapeutics-announces-up-to-$250-million-credit-facility-with-perceptive-advisors</link><title>Autolus Therapeutics Announces up to $250 Million Credit Facility With Perceptive Advisors</title><description>&lt;p&gt;&lt;strong&gt;Reston – August 3, 2026 –&lt;/strong&gt; Cooley advised Autolus Therapeutics (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, on its &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/08/03/3337385/0/en/autolus-therapeutics-reports-preliminary-second-quarter-2026-net-product-revenue-and-announces-credit-facility-of-up-to-250-million-with-perceptive-advisors.html" target="_blank"&gt;strategic financing with Perceptive Advisors for the sale of notes of up to $250 million in aggregate principal amount in a five-year, interest-only senior credit facility&lt;/a&gt;, subject to certain conditions. An initial $75 million principal amount of notes has been issued by Autolus to Perceptive on July 30, 2026, and an additional $25 million in aggregate principal amount will be available at Autolus’ option for up to six months post-closing. An additional $150 million in aggregate principal amount of subsequent capital may become available in separate tranches upon achievement of certain pre-specified revenue milestones.&lt;/p&gt;
&lt;p&gt;Lawyers Christian Plaza, Mischi a Marca, John Clark and Matthew Scarano led the cross-border US and UK Cooley team advising Autolus, with support from Jackson Alldredge, Xueqing Li, Shehzad Akram and Kavi Huded. The team also included tax lawyers David Wilson, Aaron Pomeroy and Jack Jones, life sciences partnering lawyers Kenneth Krisko and Stephanie Palmer and corporate and securities lawyers Claire Keast-Butler and William DuVal. Francis Wheeler provided opinion committee review.&lt;/p&gt;
&lt;p&gt;Cooley previously advised Autolus on its&amp;nbsp;&lt;a href="https://www.cooley.com/news/coverage/2018/2018-07-09-autolus-173-million-ipo"&gt;$173 million initial public offering in July 2018&lt;/a&gt;, &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/en/news-release/2020/01/27/1975709/0/en/Autolus-Announces-Closing-of-Public-Offering.html" target="_blank"&gt;$80 million follow-on offering in January 2020&lt;/a&gt;, &lt;a rel="noopener noreferrer" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-announces-closing-public-offering-and-full-exercise-0" target="_blank"&gt;$115 million follow-on offering in February 2021&lt;/a&gt;, &lt;a rel="noopener noreferrer" href="https://autolus.gcs-web.com/news-releases/news-release-details/blackstone-life-sciences-invest-250-million-autolus-therapeutics/" target="_blank"&gt;strategic collaboration and financing with Blackstone in November 2021&lt;/a&gt;, &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/en/news-release/2022/12/09/2570762/0/en/Autolus-Announces-Pricing-of-Public-Offering.html" target="_blank"&gt;$150 million follow-on offering in December 2022&lt;/a&gt;, &lt;a rel="noopener noreferrer" href="https://autolus.gcs-web.com/news-releases/news-release-details/biontech-and-autolus-announce-strategic-car-t-cell-therapy" target="_blank"&gt;strategic collaboration with BioNTech in February 2024&lt;/a&gt; and &lt;a href="https://www.cooley.com/news/coverage/2024/2024-02-08-autolus-announces-strategic-collaboration-with-biontech-350-million-underwritten-offering"&gt;$350 million underwritten offering in February 2024&lt;/a&gt;.&lt;/p&gt;</description><pubDate>Mon, 03 Aug 2026 17:59:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{C8D55616-6DD0-4909-B32D-B93EBDC8B46F}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-03-cooley-shortlisted-across-multiple-categories-in-hong-kong-law-awards</link><title>Cooley Shortlisted Across Multiple Categories in Hong Kong Law Awards</title><description>&lt;p&gt;&lt;strong&gt;Hong Kong &amp;ndash; August 3, 2026&lt;/strong&gt;&amp;nbsp;&lt;strong&gt;&amp;ndash;&lt;/strong&gt; Cooley has been shortlisted in five categories in the Asian Legal Business Hong Kong Law Awards 2026, which honor the exceptional performance of both private practitioners and in-house counsel in Hong Kong.&lt;/p&gt;
&lt;p&gt;The firm was shortlisted in two practice categories, two individual categories and one deal category:&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;Deal Firm of the Year&lt;/li&gt;
    &lt;li&gt;Investment Funds Law Firm of the Year&lt;/li&gt;
    &lt;li&gt;Dealmaker of the Year: Will Cai&lt;/li&gt;
    &lt;li&gt;Young Lawyer of the Year (Law Firm): Joyce Wang&lt;/li&gt;
    &lt;li&gt;Equity Market Deal of the Year: For its &lt;a href="https://www.cooley.com/news/coverage/2025/2025-11-05-seres-announces-hk$14-28-billion-ipo"&gt;representation of the underwriters of Seres Group in the company&amp;rsquo;s HK$14.28 billion (US$1.7 billion) initial public offering&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;This marks the second consecutive year that both Will Cai and Joyce Wang have been shortlisted for Dealmaker of the Year and Young Lawyer of the Year, respectively.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.legalbusinessonline.com/law-awards/alb-hong-kong-law-awards-2026" target="_blank"&gt;View the full shortlist&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;An awards ceremony will be held in Hong Kong on September 11.&lt;/p&gt;</description><pubDate>Mon, 03 Aug 2026 17:46:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{F50B8076-9625-4123-96DB-102C79AF7154}</guid><link>https://www.cooley.com/news/coverage/2026/2026-08-03-mariana-minerals-raises-$310-million-series-b</link><title>Mariana Minerals Raises $310 Million Series B </title><description>&lt;p&gt;&lt;strong&gt;Seattle – August 3, 2026 –&lt;/strong&gt; Cooley advised Mariana Minerals, the world’s only software‑first minerals project developer and operator focused on supplying the minerals critical to modern energy, AI, and defense technologies, on its &lt;a rel="noopener noreferrer" href="https://marianaminerals.com/news/series-b-announcement" target="_blank"&gt;$310 million Series B financing&lt;/a&gt;. This round brings the company’s total parent and project capital raised to date to approximately $400 million.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;The round was led by Khosla Ventures, with continued support from Andreessen Horowitz (a16z) and Breakthrough Energy Ventures, and new participation from Greenoaks, Halo Fund, Pax Ventures, StepStone Group, BHP Ventures, Washington Harbour Partners, Greycroft, General Innovation Capital Partners, Mitsubishi Corporation, In-Q-Tel (IQT), and Earthshot Ventures, with a number of additional strategic capital partners joining the round.&lt;/p&gt;
&lt;p&gt;Lawyers Colleen Badgley, Willy Cowles, Jared Abes and Joe Honeycutt led the Cooley team advising Mariana Minerals.&lt;/p&gt;</description><pubDate>Mon, 03 Aug 2026 15:47:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{0819B2F3-69A4-4F72-9066-A01FE1B61720}</guid><link>https://www.cooley.com/news/insight/2026/2026-08-03-eu-ai-act-transparency-obligations-take-effect-2-august-2026</link><title>EU AI Act: Transparency Obligations Take Effect 2 August 2026</title><description>&lt;p&gt;Starting 2 August 2026, providers and deployers of certain AI systems must comply with the transparency obligations set out in Article 50 of the EU Artificial Intelligence Act (Regulation (EU) 2024/1689) (AI Act). The European Commission adopted guidelines on these obligations on 20 July 2026. Noncompliance can trigger fines of up to &amp;euro;15 million or 3% of worldwide annual turnover, whichever is higher. The AI Act applies globally to providers, deployers, importers and distributors of AI systems that place AI on the EU market or whose AI outputs are used within the European Union.&lt;/p&gt;
&lt;h3&gt;What the rules cover&lt;/h3&gt;
&lt;p&gt;Article 50 addresses four scenarios, split between obligations on providers (those who develop and place an AI system on the market) and deployers (those who use an AI system under their own authority):&lt;/p&gt;
&lt;ol&gt;
    &lt;li&gt;AI systems that interact directly with individuals (e.g., chatbots, voice assistants, AI agents): Providers must disclose that users are engaging with AI, unless this is already obvious.&lt;/li&gt;
    &lt;li&gt;AI systems generating or manipulating synthetic audio, image, video or text: Providers must embed machine-readable markings and provide a detection mechanism, subject to limited exceptions (e.g., standard editing, non-substantial alterations).&lt;/li&gt;
    &lt;li&gt;Emotion recognition or biometric categorization systems: Deployers must inform affected individuals.&lt;/li&gt;
    &lt;li&gt;Deep fakes and AI-generated text on public-interest matters: Deployers must disclose that content was artificially generated or manipulated, unless it has undergone substantive human editorial review with a person assuming editorial responsibility.&lt;/li&gt;
&lt;/ol&gt;
&lt;h3&gt;Key dates and transitional relief&lt;/h3&gt;
&lt;p&gt;The obligations apply immediately from 2 August 2026 to all in-scope systems, regardless of when they were placed on the market. Content generated and published before that date need not be retroactively labeled. A limited transitional period applies only to the marking and detection obligation for generative AI systems already on the market. Providers have until 2 December 2026 to comply.&lt;/p&gt;
&lt;h3&gt;The Code of Practice&lt;/h3&gt;
&lt;p&gt;The AI Office has published a voluntary Code of Practice on Transparency of AI-Generated Content, offering providers a recognized path to demonstrate compliance with the marking and detection obligations. This includes a set of icons that may be used to label AI-generated content. Several major AI providers have already signed on. Signatories benefit from a degree of presumption of conformity and a more favorable enforcement posture; non-signatories face closer scrutiny and must demonstrate compliance through other means.&lt;/p&gt;
&lt;h3&gt;What businesses should do now&lt;/h3&gt;
&lt;ul&gt;
    &lt;li&gt;Identify which AI systems you provide or deploy, and under whose authority they operate (including where agencies or contractors are involved).&lt;/li&gt;
    &lt;li&gt;Map content and interactions against the four categories above, including deep fakes and public-interest text.&lt;/li&gt;
    &lt;li&gt;Implement disclosure, labeling and editorial-review procedures, and assess whether to sign the Code of Practice.&lt;/li&gt;
    &lt;li&gt;Complete this assessment before 2 August 2026, noting the extended 2 December 2026 deadline for marking/detection of existing generative AI systems.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;If you have questions about how these obligations apply to your organization, please contact your Cooley team.&lt;/p&gt;</description><pubDate>Mon, 03 Aug 2026 07:00:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{44FF75E1-79F0-4B27-95EA-E9C1C5CE6E5B}</guid><link>https://www.cooley.com/news/insight/2026/2026-07-31-foreign-produced-power-inverters-and-advanced-robotic-devices-added-to-fcc-covered-list</link><title>Foreign-Produced Power Inverters and Advanced Robotic Devices Added to FCC Covered List</title><description>&lt;p&gt;On July 28, 2026, the Federal Communication Commission&amp;rsquo;s Public Safety and Homeland Security Bureau &lt;a rel="noopener noreferrer" href="https://docs.fcc.gov/public/attachments/DA-26-786A1.pdf" target="_blank"&gt;announced the addition of foreign-produced power inverters and advanced robotic devices to the Covered List&lt;/a&gt;. This action, which took effect immediately, follows national security determinations (NSDs) that these devices pose supply chain vulnerabilities and cybersecurity risks to critical infrastructure.&lt;/p&gt;
&lt;h3&gt;Advanced robotic devices&lt;/h3&gt;
&lt;p&gt;The FCC&amp;rsquo;s action on advanced robotic devices also follows an &lt;a rel="noopener noreferrer" href="https://www.fcc.gov/sites/default/files/robots-nsd.pdf" target="_blank"&gt;NSD that advanced robotic devices are being increasingly used in monitoring and securing critical infrastructure&lt;/a&gt;, as well as being applied across the industrial manufacturing sector, and are vulnerable to data exfiltration, remote disruption and dependencies on unsecure over-the-air updates.&lt;/p&gt;
&lt;p&gt;The NSD&amp;rsquo;s definition of &amp;ldquo;advanced robotic device,&amp;rdquo; as adopted by the FCC, is a mechanical mobile device that satisfies the following four prongs:&lt;/p&gt;
&lt;ol&gt;
    &lt;li&gt;Is capable of locomotion, obstacle avoidance, navigation or movement on the ground.&lt;/li&gt;
    &lt;li&gt;Operates at a distance from a human operator or supervisor based on commands or in response to sensor data or any combination thereof.&lt;/li&gt;
    &lt;li&gt;Has a combined weight of the device and, if applicable, ground station or docking station of more than 4.4 pounds.&lt;/li&gt;
    &lt;li&gt;Contains:&lt;/li&gt;
    &lt;ul style="margin-left: 40px;"&gt;
        &lt;li&gt;A sensor capable of perceiving its environment.&lt;/li&gt;
        &lt;li&gt;A component capable of providing network connectivity with connection speeds of at least 200 kbps in either direction.&lt;/li&gt;
        &lt;li&gt;Software running either locally or remotely that controls the robot&amp;rsquo;s autonomous navigation or movement perception, data collection or remote command and control.&lt;/li&gt;
    &lt;/ul&gt;
    &lt;p&gt;The defiition explicitly includes autonomous mobile robots, humanoid robots and quadrupeds with such capabilities, but encompasses other devices that fall within the four prongs. The rule appears to apply to many home robotics products, such as robotic vacuums, lawn mowers and comparable products, along with terrestrial robotic delivery devices.&lt;/p&gt;
    &lt;p&gt;The definition explicitly excludes connected vehicles, vehicles operated only on a rail line, uncrewed aircraft or uncrewed aircraft systems, unmanned underwater vehicles, fixed/nonmobile robots, or medical devices, such as surgical instruments, external limb prostheses, and ambulatory and mobility assistive devices (e.g., canes, crutches, walkers, wheelchairs).&lt;/p&gt;
    &lt;h3&gt;Power inverters&lt;/h3&gt;
    &lt;p&gt;The FCC&amp;rsquo;s action follows an &lt;a rel="noopener noreferrer" href="https://www.fcc.gov/sites/default/files/power-inverter-fcc-determination.pdf" target="_blank"&gt;NSD finding that power inverters&amp;rsquo; remote connectivity creates vulnerabilities in the US energy grid&lt;/a&gt;. These vulnerabilities could let foreign or other malicious actors access inverters and exploit such access through various cyberattacks. As described in the NSD, power inverters facilitate the connection of direct current energy generation sources to the predominately alternating current electricity of the US energy grid, and it is estimated that more than 46 GW of electric power on the grid currently relies on inverters.&lt;/p&gt;
    &lt;p&gt;While the NSD focused heavily on power inverters&amp;rsquo; connection to the grid, the &lt;a rel="noopener noreferrer" href="https://www.fcc.gov/sites/default/files/power-inverter-fcc-determination.pdf" target="_blank"&gt;NSD&amp;rsquo;s definition of &amp;ldquo;power inverter,&amp;rdquo;&lt;/a&gt; adopted by the FCC, makes no reference to the electrical grid. Specifically, under the NSD&amp;rsquo;s definition, &amp;ldquo;power inverters:&amp;rdquo;&lt;/p&gt;
    &lt;ul&gt;
        &lt;li&gt;Are any bi-directional power devices or systems that convert direct current electricity to alternating current electricity or convert alternating current electricity to direct current electricity (including microinverters, string inverters, central inverters and hybrid (battery-based) inverters).&lt;/li&gt;
        &lt;li&gt;Contain components that enable remote communication, control, sensing, data-collection or monitoring through Wi-Fi, cellular, Bluetooth or other similar connections. &lt;/li&gt;
    &lt;/ul&gt;
    &lt;p&gt;The FCC may issue guidance clarifying this definition, but we anticipate that a connected device that either converts AC-to-DC or DC-to-AC (or both) is within the definition and subject to the Covered List. Similarly, until the FCC issues guidance to the contrary, manufacturers should not assume that devices not connected to the grid are outside the scope of the definition.&lt;/p&gt;
    &lt;h3&gt;Effect of inclusion on the Covered List&lt;/h3&gt;
    &lt;p&gt;Products placed on the Covered List cannot receive FCC equipment authorization, which effectively prevents such products from being marketed and sold in the US. The action only applies to new foreign-produced power inverters and advanced robotic devices that have not received equipment authorization prior to July 28, 2026. Devices that were granted authorization by the FCC before that date can continue to be sold in the US. Companies that produce power inverters or advanced robotic devices outside of the US can seek Conditional Approval from the Department of War or Department of Homeland Security (DHS) to exempt their devices from the Covered List going forward.&lt;/p&gt;
    &lt;h3&gt;Opportunities to mitigate effects&lt;/h3&gt;
    &lt;h4&gt;Waiver of certain &amp;lsquo;permissive changes&amp;rsquo; prohibitions&lt;/h4&gt;
    &lt;p&gt;On the same day, the FCC also &lt;a rel="noopener noreferrer" href="https://docs.fcc.gov/public/attachments/DA-26-789A1.pdf" target="_blank"&gt;announced a waiver that permits previously authorized power inverters and advanced robotic devices to receive basic software and firmware updates&lt;/a&gt; that mitigate harm to US consumers, such as changes that ensure the continued functionality of the device (e.g., vulnerability patches and updates to facilitate compatibility with different operating systems). Accordingly, any foreign-produced power inverters or advanced robotic devices that were authorized prior to July 28, 2026, may undergo these permissive changes through at least January 1, 2029.&lt;/p&gt;
    &lt;p&gt;Producers may also be able to petition for a waiver to make certain Class I and Class II permissive changes to hardware of already certified devices. Such permissive hardware changes should not:&lt;/p&gt;
    &lt;ul&gt;
        &lt;li&gt;Improve performance or capability or alter the functionality of the previously authorized device.&lt;/li&gt;
        &lt;li&gt;Be used to market the device as a distinct model.&lt;/li&gt;
        &lt;li&gt;Involve swapping a US-produced component for a foreign-produced component.&lt;/li&gt;
    &lt;/ul&gt;
    &lt;p&gt; The FCC has &lt;a rel="noopener noreferrer" href="https://docs.fcc.gov/public/attachments/DA-26-642A1.pdf" target="_blank"&gt;granted similar waivers for permissive changes to hardware in routers&lt;/a&gt; with existing authorizations that were subsequently placed on the Covered List.&lt;/p&gt;
    &lt;h3&gt;&amp;lsquo;Conditional Approval&amp;rsquo;&lt;/h3&gt;
    &lt;p&gt;Producers of power inverters and advanced robotic devices on the Covered List may apply for Conditional Approval that would exempt the approved entity from Covered List restrictions. As with &lt;a href="https://www.cooley.com/news/insight/2026/2026-03-26-fcc-moves-to-prevent-new-foreign-routers"&gt;other devices that are included on the Covered List&lt;/a&gt;, entities seeking Conditional Approval for foreign-produced power inverters or advanced robotic devices must be prepared to provide information on the entity&amp;rsquo;s corporate and management structure, details regarding existing manufacturing and component supply chain, and a US manufacturing and onshoring plan.&lt;/p&gt;
    &lt;h3&gt;What affected companies can do now&lt;/h3&gt;
    &lt;p&gt;If your company manufactures, distributes or integrates these devices, you should consider the following immediate steps:&lt;/p&gt;
    &lt;h4&gt;1. Audit your devices&lt;/h4&gt;
    &lt;ul&gt;
        &lt;li&gt;&lt;strong&gt;Identify country of origin:&lt;/strong&gt; Determine exactly where your current and future devices are manufactured. Under the new rule, even &amp;ldquo;American&amp;rdquo; brands may be affected if their physical production occurs in a foreign country.&amp;nbsp;&lt;/li&gt;
        &lt;li&gt;&lt;strong&gt;Assess &amp;ldquo;foreign-produced&amp;rdquo; models:&lt;/strong&gt; If only minor assembly of a product happens abroad, you may be able to demonstrate that it should not be on the Covered List.
        &lt;/li&gt;
        &lt;li&gt;&lt;strong&gt;Identify &amp;ldquo;previously authorized&amp;rdquo; models:&lt;/strong&gt; Confirm which of your foreign-produced models already have an approved FCC ID. These can still be imported and sold. But consider whether permissive changes to hardware are or will be needed due to supply chain issues or end-of-life status.&lt;/li&gt;
        &lt;li&gt;&lt;strong&gt;Pipeline review:&lt;/strong&gt; Any new models currently in development abroad will likely be blocked from the US market unless you obtain Conditional Approval or pivot your manufacturing strategy.
        &lt;/li&gt;
    &lt;/ul&gt;
    &lt;h4&gt;&lt;/h4&gt;
    &lt;h4&gt;2. Apply for &amp;lsquo;Conditional Approval&amp;rsquo;&lt;/h4&gt;
    &lt;p&gt;The FCC has provided a pathway for exemptions from the Covered List through the Department of War and DHS. To succeed, applicants should be prepared to provide:&lt;/p&gt;
    &lt;ul&gt;
        &lt;li&gt;Detailed background about company ownership and management.&lt;/li&gt;
        &lt;li&gt;A detailed bill of materials and country of origin for all components of each device for which Conditional Approval is sought.&lt;/li&gt;
        &lt;li&gt;A verifiable US manufacturing and onshoring plan that is time-bound, including expected capital expenditures and workforce deployment, and overseen by a dedicated officer.&lt;/li&gt;
        &lt;li&gt;Quarterly updates on the progress of bringing production to US soil.&lt;/li&gt;
    &lt;/ul&gt;
    &lt;h4&gt;3. Secure your legacy devices&lt;/h4&gt;
    &lt;ul&gt;
        &lt;li&gt;Take advantage of the FCC Office of Engineering and Technology waiver for Class I and Class II permissive changes for previously authorized advanced robotic devices and power inverters to receive software and firmware updates to mitigate security harms. This waiver is currently set to expire on January 1, 2029. Ensure you have a plan to push security updates to existing foreign-made advanced robotic devices and power inverters before the waiver window potentially narrows or expires.&lt;/li&gt;
        &lt;li&gt;Consider filing a Petition for Waiver to permit Class I and Class II permissive changes to certain hardware that are, or are expected to become, subject to supply chain issues or end-of-life status.&lt;/li&gt;
    &lt;/ul&gt;
    &lt;h4&gt;4. Update certifications&lt;/h4&gt;
    &lt;p&gt;Going forward, all applicants for FCC equipment authorization who have a product on the Covered List will need to self-certify, in good faith, that their device is not &amp;ldquo;covered equipment.&amp;rdquo; False certifications could lead to significant legal exposure and the revocation of existing authorizations.&lt;/p&gt;
&lt;/ol&gt;</description><pubDate>Fri, 31 Jul 2026 19:37:38 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{A2FBCCE9-EA1D-4E58-8A4B-4186DDFE4DEE}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-31-swervepay-obtains-fraud-judgment-awarding-$120-million</link><title>SwervePay Obtains Fraud Judgment Awarding $120 Million</title><description>&lt;p&gt;&lt;strong&gt;Denver and Boston &amp;ndash; July 31, 2026 &amp;ndash;&lt;/strong&gt; Cooley secured a post-trial judgment for its e-payment facilitator client SPOSC Investment Holdings, formerly known as SwervePay, in the Delaware Court of Chancery, resulting in approximately $120 million in fraud damages plus prejudgment interest, bringing the total award to approximately $150 million.&lt;/p&gt;
&lt;p&gt;Following a five-day bench trial, Chancellor Kathaleen St. J. McCormick found that New Mountain Capital and investor Robert Wechsler fraudulently induced SwervePay to sell itself by misrepresenting the payments-volume opportunity underlying a post-closing earnout. The 102-page opinion entered judgment for the sellers on their fraud claims and awarded $43.75 million for the cash earnout, $75.69 million for the equity earnout and $656,923 for rollover units, together with prejudgment and post-judgment interest.&lt;/p&gt;
&lt;p&gt;The dispute arose from New Mountain&amp;rsquo;s 2019 acquisition of SwervePay. During negotiations, the buyers represented that Ontario Systems, another portfolio company of New Mountain, had approximately $34 billion in payments volume available for monetization through SwervePay&amp;rsquo;s platform. Internal communications later showed that, internally, the buyers were relying on an estimate of monetizable payment volume closer to $5 billion.&lt;/p&gt;
&lt;p&gt;The court found that the buyers nevertheless used the larger figure to persuade SwervePay and its board that the earnout was achievable. In describing the buyers&amp;rsquo; intent to fraudulently induce the transaction, Chancellor McCormick wrote that it was &amp;ldquo;plain as day.&amp;rdquo; Applying benefit-of-the-bargain damages, the court awarded SwervePay the value of the earnouts it would have received had the represented payments volume been true.&lt;/p&gt;
&lt;p&gt;The Cooley team was led by partners Orion Armon and Luke Cadigan, with Noah Pittard, Tim Cook, Katelyn Kang, Keegan N. Trofatter, Mikhaila Fogel and Celene Chen.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;a href="-/media/06513f50d53340a5af980c4119644bad.ashx"&gt;Read the order&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;The case is &lt;em&gt;In re SwervePay Acquisition, LLC&lt;/em&gt; (Consolidated C.A. No. 2021-0447-KSJM). &amp;nbsp;&lt;/p&gt;</description><pubDate>Fri, 31 Jul 2026 19:30:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{3B4EDA5C-B3AB-437D-9457-5BBBDD20D5C5}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-31-litigator-of-the-week-runners-up-and-shout-outs</link><title>Litigator of the Week Runners-Up and Shout-Outs</title><description>&lt;p&gt;A Cooley team earned a shout out on The American Lawyer&amp;rsquo;s Litigator of the Week Runners-Up and Shout-Outs list for representing Zillow Inc. and affiliated companies in securing dismissal of claims challenging the company&amp;rsquo;s referral platform and mortgage business. US District Senior Judge James Robart granted Zillow&amp;rsquo;s motion to dismiss, finding that the challenged arrangements were clearly outlined in Zillow's Terms of Use agreement and other disclosures.&lt;/p&gt;
&lt;p&gt;The Cooley team was led by partners Benedict Hur, Michelle Rogers, Aarti Reddy and Kate Goodman, and associates Sara Porter, Thilini Chandrasekera, Amber Feng and Ben Sweeney.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.law.com/litigationdaily/2026/07/31/litigator-of-the-week-runners-up-and-shout-outs/" target="_blank"&gt;Read the article (subscription required)&lt;/a&gt;&lt;/p&gt;</description><pubDate>Fri, 31 Jul 2026 16:21:37 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{2E3E37EB-C522-4532-AE4C-2F3B38FA1293}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-31-cooley-named-key-player-by-india-business-law-journal</link><title>Cooley Named Key Player by India Business Law Journal</title><description>&lt;p&gt;&lt;strong&gt;Singapore &amp;ndash; July 31, 2026 &amp;ndash;&lt;/strong&gt; Cooley was recognized as a Key Player in India Business Law Journal&amp;rsquo;s (IBLJ) 2026 report on top foreign law firms for India-related matters.&lt;/p&gt;
&lt;p&gt;In the report, IBLJ highlighted Cooley&amp;rsquo;s representation of ChrysCapital in the closing of its record-setting US$2.2 billion 10th fund, the largest private equity fundraise in India&amp;rsquo;s history. The publication also recognized Cooley&amp;rsquo;s work advising Reliance Industries on its joint venture with Meta and noted the additions of partners Shashwat Tewary and David He to the firm&amp;rsquo;s India-focused team.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://law.asia/top-foreign-firms-india-2026/" target="_blank"&gt;Read the full report&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;The report draws on an analysis of more than 600 law firms that advised on deals and disputes with an Indian connection over the past year.&lt;/p&gt;</description><pubDate>Fri, 31 Jul 2026 14:36:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{CA49695F-91AE-40D8-B29A-936DF2409EDE}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-30-cooley-advises-professional-fighters-league-on-merger-with-most-valuable-promotions</link><title>Cooley Advises Professional Fighters League on Merger With Most Valuable Promotions</title><description>&lt;p&gt;&lt;strong&gt;Reston &amp;ndash; July 30, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised the Professional Fighters League (PFL), a global mixed martial arts organization and one of the world&amp;rsquo;s leading combat sports properties, on &lt;a rel="noopener noreferrer" href="https://pflmma.com/news/most-valuable-promotions-and-professional-fighters-league-merge-to-create-a-new-global-combat-sports-platform-powerhouse" target="_blank"&gt;a landmark merger with Most Valuable Promotions&lt;/a&gt; (MVP), a combat sports company co-founded by Jake Paul and Nakisa Bidarian. The combined company, which will operate under the MVP banner, will be led by co-founders and board members Paul and Bidarian, with John Martin serving as CEO and board member.&lt;/p&gt;
&lt;p&gt;Lawyers Mike Lincoln, Adam Longenbach, Eileen Marshall, Edward Sniezek, Ga&amp;euml;l Hagan and Adam Chase led the Cooley team advising PFL.&lt;/p&gt;
&lt;p&gt;Cooley previously advised PFL on &lt;a href="https://www.cooley.com/news/coverage/2026/2026-01-21-cooley-advises-professional-fighters-league-on-strategic-capital-raise" target="_self"&gt;the completion of a successful strategic capital raise in January 2026&lt;/a&gt;.&lt;/p&gt;</description><pubDate>Thu, 30 Jul 2026 14:50:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{FE9633BE-B159-4A79-947D-BBCFA92CF692}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-30-procore-technologies-to-acquire-dronedeploy-for-approximately-$845-million</link><title>Procore Technologies to Acquire DroneDeploy for Approximately $845 Million</title><description>&lt;p&gt;Cooley advised Procore Technologies, the leading global provider of construction management software, on its agreement to acquire DroneDeploy, the robotics and visual intelligence platform for the built world that is used on over 3 million jobsites across more than 180 countries. Procore will acquire DroneDeploy for approximately $845 million in cash, subject to customary purchase price adjustments.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;In connection with the transaction, Cooley also advised Procore on obtaining a commitment for a bridge financing of up to $700 million to finance a portion of the acquisition consideration.&lt;/p&gt;
&lt;p&gt;The transaction was announced publicly in the following press release, which can be viewed&amp;nbsp;&lt;a rel="noopener noreferrer" href="https://www.businesswire.com/news/home/20260729981737/en/Procore-to-Acquire-DroneDeploy-Creating-Next-Generation-Platform-That-Sees-Understands-and-Acts-on-the-Jobsite" target="_blank"&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Garth Osterman, Erin Kirchner, Mischi a Marca, Adam Longenbach, Logan Tiari, Jon Avina, Anne Luquette, Tracy Rubin, Eileen Marshall, Austin Holt, and Allison NostDahl led the Cooley team advising Procore.&lt;/p&gt;
&lt;p&gt;Joanna Leung, Brionne Frazier, Yoni Horn, Matt Kong, Amanda Pacheco, Megan Browdie, Stella Sarma, Kristen Matthews, Cristina DeBiase, and Sharon Connaugton provided invaluable support.&lt;/p&gt;
&lt;p&gt;Cooley has served as Procore Technologies&amp;rsquo; primary corporate and transactional counsel for over a decade. During that time, the firm has advised the company on a variety of matters, including the acquisitions of BIManywhere (2018), LaborChart (2021), Unearth Technologies (2023), and Datagrid AI (2026). Cooley also advised Procore on its $30 million Series E financing (2015), $80 million Series F financing (2016), $50 million Series G financing (2016), $75 million Series H financing (2018), and its approximately $700 million IPO (2021).&lt;/p&gt;</description><pubDate>Thu, 30 Jul 2026 13:53:48 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{B7B4BF0D-BE12-4BDF-9696-584EAE5D30C0}</guid><link>https://www.cooley.com/news/insight/2026/2026-07-29-mailbox-to-inbox-the-secs-proposed-e-delivery-rules-and-what-employers-need-to-know-now</link><title>Mailbox to Inbox: The SEC’s Proposed E-Delivery Rules and What Employers Need to Know Now</title><description>&lt;p&gt;Federal securities laws impose delivery obligations on companies in connection with director and executive incentive equity compensation programs &amp;ndash; from Form S-8 prospectuses to equity award agreements and even tender offer materials. Now, those rules may change in a significant way. The Securities and Exchange Commission (SEC) recently proposed Regulation E-Delivery, a sweeping new rule that would dramatically expand the ability of issuers and others to satisfy information delivery requirements electronically.&lt;/p&gt;
&lt;p&gt;That proposed regulation is the subject of a &lt;a href="https://www.cooley.com/news/insight/2026/2026-07-21-from-opt-in-to-opt-out-sec-proposes-electronic-delivery-as-default-for-required-disclosures"&gt;July 21 Cooley alert&lt;/a&gt;, and we encourage you to read that alert to understand the potential sweeping significance of the proposed rule.&amp;nbsp; The purpose of &lt;strong&gt;this&lt;/strong&gt; alert is to highlight some of the relief around electronic delivery that already applies in the employer-employee context pending final approval of the proposed Regulation E-Delivery rule in whatever form that might take.&lt;/p&gt;
&lt;h3&gt;How we got here&lt;strong style="letter-spacing: 0.48px;"&gt;&amp;nbsp; &amp;nbsp;&amp;nbsp;&lt;/strong&gt;&lt;/h3&gt;
&lt;p&gt;Many required regulatory disclosures and reports under the federal securities laws have long been delivered in paper format. As internet and email access began to expand in the 1990s, the SEC began issuing interpretive guidance that permitted electronic delivery in some circumstances, provided generally that the person with a right to receive the applicable disclosures and reports affirmatively consented to e-delivery. In a &lt;a rel="noopener noreferrer" href="https://www.sec.gov/rules-regulations/2000/04/use-electronic-media#P298_90029" target="_blank"&gt;2000 Interpretive Release&lt;/a&gt;, the SEC resisted calls to expand e-delivery opportunities first provided in 1995/1996 releases. For example, in 2000, the SEC expressly concluded that the time had not yet come for an &amp;ldquo;access-equals-delivery&amp;rdquo; model, where investors would be assumed to have access to the internet, thereby allowing delivery to be accomplished solely by an issuer posting a document on the issuer&amp;rsquo;s or a third party&amp;rsquo;s website.&lt;/p&gt;
&lt;p&gt;At the same time, the SEC in those 1995/1996 releases recognized that special relief is appropriate in the employer-employee context. At the heart of that relief is how to demonstrate evidence of delivery, one of the three elements of satisfactory electronic delivery in the current framework (along with notice and access). The &lt;a rel="noopener noreferrer" href="https://www.sec.gov/files/rules/interp/33-7233.txt" target="_blank"&gt;1995 release (Securities Act Release No. 7233 (Oct. 6, 1995))&lt;/a&gt; provided that one method for satisfying the evidence-of-delivery element is to obtain an informed consent from an investor to receive information through a particular electronic medium. The &lt;a rel="noopener noreferrer" href="https://www.sec.gov/files/rules/interp/33-7288.txt" target="_blank"&gt;1996 release (Securities Act Release No. 7288 (May 9, 1996))&lt;/a&gt; then provided that an issuer could presume consent to electronic delivery by employee-security holders who use the electronic mail system &amp;ldquo;in the ordinary course of performing their duties and ordinarily are expected to log-on to electronic mail routinely to receive mail and communications.&amp;rdquo;&lt;/p&gt;
&lt;h3&gt;What this looks like in practice: Equity incentive plans and Form S-8&lt;/h3&gt;
&lt;p&gt;One critical example of where this relief is in play are the following e-delivery rules presently applicable to employers awarding grants under equity incentive plans in reliance on an S-8 registration statement based on the guidance from the 1995/1996 releases:&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;&lt;strong&gt;Presumed consent; access.&lt;/strong&gt; As noted above, an employer generally may presume consent to e-delivery by employees who are regular email users or, for those who are not regular email users, are able to receive e-delivery via other means, such as through administrative assistants or co-workers. However, the email must prominently state that a paper copy is available upon request, and the employer must in fact make paper copies available to any employee who asks.&lt;/li&gt;
    &lt;li&gt;&lt;strong&gt;Former employees.&lt;/strong&gt; Because of an expectation that former employees and service providers no longer have routine workplace access, former employees and service providers must provide informed consent to e-delivery.&lt;/li&gt;
    &lt;li&gt;&lt;strong&gt;Form of delivery. &lt;/strong&gt;The applicable materials can be attached to the e-delivery vehicle (for instance as attachments to an email) or, where documents are not directly attached , the e-delivery must provide employees and service providers with the information necessary to easily locate and retrieve them (&lt;strong&gt;g.&lt;/strong&gt;, directions for accessing them through the company&amp;rsquo;s local area network or a third-party provider&amp;rsquo;s equity program portal). The access medium must &amp;ldquo;not be so burdensome that intended recipients cannot effectively access the information provided,&amp;rdquo; and recipients must have the opportunity to retain the documents or have ongoing access equivalent to personal retention.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;The employer-employee relief is not limited to S-8 circumstances, however, and it can prove very useful in other employee compensation circumstances as well, such as issuer tender offers.&lt;/p&gt;
&lt;h3&gt;What now: What&amp;rsquo;s next?&lt;/h3&gt;
&lt;p&gt;Proposed Regulation E-Delivery will likely establish new, uniform standards for electronic delivery of securities disclosures and reports &amp;ndash; including the 10(a) prospectus under Form S-8. But the finish line is not here yet. In the meantime, compliance obligations under the current framework are fully effective, and the employer-employee e-delivery relief described above is available to use right now. Taking full advantage of existing relief requires attention to the details.&lt;/p&gt;
&lt;p&gt;The applicable requirements are numerous and include rules that are easy to overlook &amp;ndash;proper legending, maintaining a file of all prospectus materials for at least five years after they were last used, and the delivery rules that are the focus of this alert. Gaps in any of these areas can result in adverse consequences for your company and your employees, and the SEC&amp;rsquo;s rule proposal is a timely reminder that employers should be aware of the obligations and monitoring compliance with them on an ongoing basis. Cooley&amp;rsquo;s compensation and benefits group is ready to help you assess your current practices, close any gaps and position your program for the changes ahead. Reach out to your Cooley contact to get started.&lt;/p&gt;</description><pubDate>Wed, 29 Jul 2026 19:44:16 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{D88B63AF-1B00-4275-8083-A400AFC3BC24}</guid><link>https://www.cooley.com/news/insight/2026/2026-07-29-quantum-computing-eos-create-immediate-compliance-deadlines-new-federal-partnership-opportunities</link><title>Quantum Computing EOs Create Immediate Compliance Deadlines, New Federal Partnership Opportunities</title><description>&lt;p&gt;On June 22, 2026, President Donald Trump signed two executive orders (EOs) that make quantum computing a concrete compliance and business reality for critical infrastructure operators, federal agencies, federal contractors and quantum technology companies. The first order focuses on the threats posed by a quantum future and sets hard deadlines for migrating federal systems and contractor operations to post-quantum cryptography (PQC), with initial agency steps due by late July 2026. The second order launches a coordinated federal push to develop the most advanced quantum technologies in the world, creating significant partnership opportunities for the private sector.&lt;/p&gt;
&lt;p&gt;This alert summarizes the key provisions, deadlines and action items arising from these orders. In light of the growing importance of quantum computing to organizations&amp;rsquo; cybersecurity, privacy and data regulatory concerns, Cooley&amp;rsquo;s cyber/data/privacy practice will be publishing an ongoing series of alerts to keep you informed about what&amp;rsquo;s to come.&lt;/p&gt;
&lt;h3&gt;Overview: Two orders, two missions&lt;/h3&gt;
&lt;p&gt;&lt;a href="https://www.whitehouse.gov/presidential-actions/2026/06/securing-the-nation-against-advanced-cryptographic-attacks/"&gt;Executive Order 14412&lt;/a&gt;, titled &amp;ldquo;Securing the Nation Against Advanced Cryptographic Attacks&amp;rdquo; (Defensive Order), focuses on US defense and preparedness against the threats posed by quantum computing. It responds to a threat that the Trump administration understands to already be materializing: Adversaries are collecting sensitive encrypted data today with the intention of decrypting it later, once large-scale quantum computers are operational. This &amp;ldquo;harvest now, decrypt later&amp;rdquo; strategy means the window for action is defined not by when quantum computers arrive, but by when organizations complete their migrations to quantum-resilient safeguards. Experts have been aware of this attack strategy for some time, since the algorithms underlying the widespread distribution of public key cryptography (such as RSA and elliptic curve) produce output using mathematical computations that make that output feasible to decryption in a reasonable period of time with quantum technology. To counter this, the Defensive Order mandates a government-wide transition to post-quantum cryptography (PQC), meaning encryption algorithms specifically designed to withstand attacks by both quantum computers and the classical computers in use today. Federal contractors and critical infrastructure operators, as defined under the USA PATRIOT Act, are squarely in scope.&lt;/p&gt;
&lt;p&gt;&lt;a href="https://www.whitehouse.gov/presidential-actions/2026/06/ushering-in-the-next-frontier-of-quantum-innovation/"&gt;Executive Order 14413&lt;/a&gt;, titled &amp;ldquo;Ushering In the Next Frontier of Quantum Innovation&amp;rdquo; (Innovation Order), focuses on US innovation and achieving primacy in the quantum technology space. It directs a whole-of-government effort to:&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;Develop a quantum computer capable of scientific discoveries beyond anything currently possible on a classical computer.&lt;/li&gt;
    &lt;li&gt;Accelerate quantum sensing and networking capabilities.&lt;/li&gt;
    &lt;li&gt;Strengthen domestic supply chains for quantum hardware and components.&lt;/li&gt;
    &lt;li&gt;Grow a trained US quantum workforce.&lt;/li&gt;
    &lt;li&gt;Entrench US global leadership in quantum technology.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;The Innovation Order also serves as a call to the private sector, signaling the federal government actively seeks industry partners.&lt;/p&gt;
&lt;h3&gt;Immediate deadlines for federal agencies&lt;/h3&gt;
&lt;p&gt;For federal agencies, the deadlines in the Defensive Order begin almost immediately. Within 30 days of its release, or by July 22, 2026, every agency head must designate a PQC migration lead, meaning an employee who will be responsible for overseeing the agency&amp;rsquo;s cryptographic inventory, developing a prioritized migration plan and coordinating across the government, and will report to the agency&amp;rsquo;s chief information officer. Within 90 days, or by September 20, 2026, the Office of Management and Budget must issue guidance requiring agencies to review their inventories of their high- value assets and high-impact systems and submit plans to transition them, with firm completion targets:&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;All high-value assets and high-impact systems must use PQC for key establishment purposes (i.e., the creation of a shared encryption key for communication between different systems) by&amp;nbsp;&lt;strong&gt;December 31, 2030&lt;/strong&gt;.&lt;/li&gt;
    &lt;li&gt;All high-value assets and high-impact systems must use PQC for digital signature purposes (i.e., for verifying the authenticity and integrity of data) by&amp;nbsp;&lt;strong&gt;December 31, 2031&lt;/strong&gt;.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;A NIST-led pilot migration on a subset of its own systems must begin within 180 days and be complete by December 31, 2027, providing a model for agencies to follow.&lt;/p&gt;
&lt;h3&gt;Implications for federal contractors&lt;/h3&gt;
&lt;p&gt;Federal contractors are not exempt. The Defensive Order requires the Federal Acquisition Regulatory Council, within 180 days, to publish a proposed rule requiring federal contractors to comply with post-quantum cryptography standards by December 31, 2030. A separate proposed rule, due within 270 days, would require federal contractors to maintain vulnerability disclosure programs and incorporate reports of cryptographic vulnerabilities into such programs, including the use of encryption methods that do not meet federal standards.&lt;/p&gt;
&lt;p&gt;These proposed rules are not yet final but will be soon. Federal contractors that begin cryptographic inventories now &amp;ndash; cataloging what systems they run, what encryption they rely on and where their gaps are &amp;ndash; will be far better positioned than those who wait for the rules to be proposed and finalized.&lt;/p&gt;
&lt;h3&gt;Implications for critical infrastructure operators&lt;/h3&gt;
&lt;p&gt;The Defensive Order extends to operators of critical infrastructure across sectors including energy, water, transportation, healthcare and financial services. The federal agencies that oversee each of these sectors are required to assist operators in developing PQC migration plans. If you operate critical infrastructure, expect outreach from your sector&amp;rsquo;s federal oversight agency. Engaging proactively now will put you ahead of that process.&lt;/p&gt;
&lt;h3&gt;Implications for quantum technology companies&lt;/h3&gt;
&lt;p&gt;For companies in the quantum technology space, the Innovation Order signals substantial federal investment and partnership opportunities. The Innovation Order directs agencies to explore advance market commitments and use prize challenges to encourage private-sector participation in building next-generation quantum computers, quantum sensors and quantum networks, as well as in developing domestic supply chains for quantum-enabling components. Companies should monitor the National Quantum Strategy update due within 180 days of the Innovation Order, which will define the specific areas of federal focus and map where the partnership opportunities will be.&lt;/p&gt;
&lt;p&gt;The Innovation Order also carries a cautionary note for quantum technology companies. The federal government intends to work with international allies to tighten restrictions on the export of quantum-enabling technologies to countries of concern and harmonize research security policies across allied nations to prevent adversarial actors from gaining access to critical quantum technology through research partnerships or other channels. For quantum technology companies, this signals that export control compliance in this space is likely to become more demanding, and that existing research collaborations with foreign universities, institutions or individuals may warrant a closer look.&lt;/p&gt;
&lt;h3&gt;Looking ahead&lt;/h3&gt;
&lt;p&gt;These EOs mark a turning point: Quantum computing is no longer a future concern but a present compliance and strategic priority. Whether your organization faces new migration obligations or stands to benefit from federal quantum investment, prompt attention to these orders is essential. Watch for the next installment in our quantum computing series, which will break down key quantum computing concepts, contextualize these orders and help enterprises and their leaders prepare for what comes next. If you have questions about either of these orders or any other quantum computing issues, please contact the Cooley cyber/data/privacy practice.&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;</description><pubDate>Wed, 29 Jul 2026 19:37:54 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{D4BE5E2F-DBF4-456B-B1F0-9C19FB99FC5D}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-29-caldera-therapeutics-announces-merger-with-synlogic-concurrent-upsized-$278-million-private-placement</link><title>Caldera Therapeutics Announces Merger With Synlogic, Concurrent Upsized $278 Million Private Placement</title><description>&lt;p&gt;&lt;strong&gt;San Francisco &amp;ndash; July 29, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised the placement agents to Caldera Therapeutics, a privately held clinical-stage biotechnology company developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease and other immune-mediated diseases, in connection with an approximately &lt;a rel="noopener noreferrer" href="https://www.businesswire.com/news/home/20260729485031/en/Synlogic-and-Caldera-Therapeutics-Announce-Merger-Agreement-and-Concurrent-Private-Placement" target="_blank"&gt;$278 million upsized private placement&lt;/a&gt; concurrent with its merger with Synlogic. The private placement included participation from a syndicate of leading healthcare institutional investors and mutual funds, including Bain Capital Life Sciences, TCGX, Atlas Venture, venBio Partners, Omega Funds, Blackstone Multi-Asset Investing, LAV, Wellington Management, Janus Henderson Investors, Sirenia Capital Management, Vivo Capital, several additional mutual funds and other institutional investors. Upon closing, the combined company plans to operate under the name Caldera Therapeutics, Inc. and intends to apply to trade on the Nasdaq Capital Market under the ticker symbol CALD.&lt;/p&gt;
&lt;p&gt;Partners Denny Won, Div Gupta and Evan Leitner led the Cooley team advising the placement agents.&lt;/p&gt;</description><pubDate>Wed, 29 Jul 2026 17:15:08 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{474F89A4-B1D7-4323-A738-C3581ACE8B0F}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-29-canoe-intelligence-to-be-acquired-by-bloomberg</link><title>Canoe Intelligence to be Acquired by Bloomberg</title><description>&lt;p&gt;Cooley advised Canoe Intelligence, a leading AI-powered data management and intelligence platform for automating private markets data collection and delivery, on its agreement to be acquired by Bloomberg, a global leader in business and financial information.&lt;/p&gt;
&lt;p&gt;The transaction was announced publicly in the following press release, which can be&amp;nbsp;viewed &lt;a rel="noopener noreferrer" href="https://www.prnewswire.com/news-releases/bloomberg-to-acquire-canoe-intelligence-taking-a-defining-step-in-its-mission-to-transform-private-markets-investing-302837466.html" target="_blank"&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Kevin Cooper, Ariel Rom, Nathan Baum, Dillon Holdsworth, and Sonida Gjonaj led the Cooley team advising Canoe Intelligence.&lt;/p&gt;
&lt;p&gt;Hanna Ali, Chelsea Andr&amp;eacute;-Vandenberg, Meghana Bhimarao, Peter Burns, Sharon Davidov, Yasmine Ebrat, Michael Egan, Alexander Ellebracht, Nicollette Kirby, &lt;span data-teams="true"&gt;Calvin&lt;/span&gt; Lee, Ryan Montgomery, Jeremy Morrison, Morgan Perna, and Stella Sarma provided invaluable support.&lt;/p&gt;
&lt;p&gt;Cooley previously advised Canoe Intelligence on its $25 million Series B financing (2023) and its $36 million Series C financing (2024).&lt;/p&gt;</description><pubDate>Wed, 29 Jul 2026 16:00:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{4711E6AB-F1E5-4C83-AB9D-965A5AB26904}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-29-vidya-therapeutics-sale-to-processa-pharmaceuticals</link><title>Vidya Therapeutics Sale to Processa Pharmaceuticals</title><description>&lt;p&gt;Cooley advised Vidya Therapeutics, a clinical-stage biotechnology company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases with an initial focus on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis, on its sale to Processa Pharmaceuticals,&amp;nbsp;a clinical-stage pharmaceutical company.&lt;/p&gt;
&lt;p&gt;The transaction was announced publicly in the following press release, which can be viewed&amp;nbsp;&lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/07/29/3335130/0/en/processa-pharmaceuticals-inc-announces-acquisition-of-vidya-therapeutics-inc-and-approximately-200-million-concurrent-private-placement-to-advance-btk-inhibitor-vt-7208-in-multiple.html" target="_blank"&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Ken Rollins, Rama Padmanabhan, Madison Jones, Brittany Wightman, and Rajdeep Bains led the Cooley corporate and M&amp;amp;A team advising Vidya Therapeutics.&lt;/p&gt;
&lt;p&gt;Sunny Liu, &amp;nbsp;John Delmastro,&amp;nbsp;Stephen Abreu, Charity Williams, Andrew Epstein, Ross Eberly, Hardy Zhou, Tony Guan, Alessandra Murata, Christopher Suhler, Julie Montejo, Dillon Jones, Benjamin Sweeney, Katie Retzbach, Carly Gibbons, Jesse Schulman, Pengli Li, Navya Dasari, Kathryn Sorenson,&amp;nbsp;Sarah Miller,&amp;nbsp;Summer Brook Lawson,&amp;nbsp;and&amp;nbsp;Taryn Wilkins&amp;nbsp;provided invaluable support.&lt;/p&gt;</description><pubDate>Wed, 29 Jul 2026 15:31:23 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{42C2A1EA-CC59-40D5-A87A-0224EE545B4E}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-29-ambiq-announces-dual-listing-on-sgx</link><title>Ambiq Announces Dual Listing on SGX</title><description>&lt;p&gt;&lt;strong&gt;Singapore – July 29, 2026 –&lt;/strong&gt; Cooley advised Ambiq Micro (New York Stock Exchange: AMBQ), a technology leader in ultra-low power semiconductor solutions for edge AI, on &lt;a rel="noopener noreferrer" href="https://www.businesswire.com/news/home/20260729712033/en/Ambiq-Expands-Global-Capital-Markets-Presence-Through-Singapore-Exchange-Mainboard-Dual-Listing" target="_blank"&gt;its listing on the Main Board of the Singapore Exchange Securities Trading Limited&lt;/a&gt; (SGX) under the ticker AMQ. The dual listing complements Ambiq's existing NYSE listing by expanding investor access across Asia and supporting the company's long-term growth strategy as demand for energy-efficient AI computing accelerates worldwide.&lt;/p&gt;
&lt;p&gt;Singapore-based lawyers Timothy Pitrelli and Steven Holm and US-based lawyers Michael Platt, Christina Roupas, Courtney Tygesson, Mateus Aboud, Alaina DeBona and David Brinton led the cross-border Cooley team advising Ambiq on its listing.&lt;/p&gt;
&lt;p&gt;Cooley previously advised Ambiq on its &lt;a href="https://www.cooley.com/news/coverage/2025/2025-07-30-ambiq-micro-announces-pricing-of-96-million-ipo"&gt;$96 million initial public offering on the NYSE in July 2025&lt;/a&gt;.&lt;/p&gt;</description><pubDate>Wed, 29 Jul 2026 13:07:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{EF563283-5AC9-4A09-B184-B869259BAD61}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-29-ferc-will-impose-reforms-if-pjm-fails-to-adopt-changes-by-september-chairman-warns</link><title>FERC Will Impose Reforms if PJM Fails to Adopt Changes by September, Chairman Warns</title><description>&lt;p&gt;Mona Dajani, partner and co-chair of Cooley&amp;rsquo;s infrastructure, energy and real estate practice, was quoted in a UtilityDive article about the Federal Energy Regulatory Commission's push to reform PJM Interconnection's governance, noting that governance has become a strategic asset amid AI-driven demand growth.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.utilitydive.com/news/ferc-pjm-governance-reforms-data-centers-capacity-market/826140/" target="_blank"&gt;Read the article&lt;/a&gt;&lt;/p&gt;</description><pubDate>Wed, 29 Jul 2026 12:16:14 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{B8CA6DD0-6E87-41B1-92C6-D76ADC69256B}</guid><link>https://www.cooley.com/news/insight/2026/2026-07-29-fcc-expands-restrictions-on-covered-list-equipment-and-supply-chains</link><title>FCC Expands Restrictions on Covered List Equipment and Supply Chains</title><description>&lt;p&gt;The Federal Communications Commission (FCC) has adopted changes to its equipment authorization rules aimed at strengthening the security of the communications supply chain.&lt;/p&gt;
&lt;p&gt;Building on its &lt;a href="~/link.aspx?_id=97CF5F25CF7F4A7388E15C26531AEECF&amp;amp;_z=z"&gt;previous actions&lt;/a&gt;, &lt;a rel="noopener noreferrer" href="https://docs.fcc.gov/public/attachments/FCC-26-50A1.pdf" target="_blank"&gt;the new Order expands&lt;/a&gt; the scope of its equipment authorization rules beyond retail products to include certain internal hardware components produced by entities prohibited from selling their products in the US because they create national security risks. (The list of these entities is known as the Covered List.) The Order also imposes new obligations on online marketplaces selling FCC-regulated devices, including requiring certain online marketplaces to display FCC IDs for certified equipment at the point of sale, subject to limitations and differentiated standards, in addition to other certification requirements for equipment modifications.&lt;/p&gt;
&lt;h3&gt;Logic-bearing hardware components&lt;/h3&gt;
&lt;p&gt;The Order closes what the FCC describes as the &amp;ldquo;component part loophole.&amp;rdquo; Until now, the FCC restricted the sale of retail products manufactured by named entities specifically named on the Covered List but did not restrict products manufactured with parts made by those entities. Under the new rules, devices incorporating &amp;ldquo;logic-bearing hardware components&amp;rdquo; produced by Covered List entities also become ineligible for FCC equipment authorization if the finished device itself would have been prohibited had it been manufactured by the Covered List entity. The FCC concluded that these components present national security risks and could permit unauthorized access, data collection or other malicious activity if they are incorporated into completed products sold in the US.&lt;/p&gt;
&lt;p&gt;To implement this new rule, the FCC adopted a definition of &amp;ldquo;logic-bearing hardware component&amp;rdquo; that encompasses nearly all hardware capable of performing digital processing functions, including devices, modules, integrated circuits and other physical components that generate and use radio frequency energy to perform data processing functions, but does not include software and firmware at this time. Thus, manufacturers, importers and other companies seeking FCC equipment authorization will need to focus on their supply chains to determine whether logic-bearing hardware components made by entities on the Covered List are used in their products.&lt;/p&gt;
&lt;h3&gt;New online marketplace requirements&lt;/h3&gt;
&lt;p&gt;The Order applies the FCC&amp;rsquo;s marketing rules to online marketplaces that list, distribute or offer regulated equipment for sale. The FCC also concludes that online marketplaces are engaged in &amp;ldquo;marketing&amp;rdquo; when they list third-party products, even if they do not take title to those particular products. In that context, the Order requires online marketplaces to display FCC IDs at the online point of sale for devices subject to FCC certification, which generally are products that use radio waves to communicate with other devices. While the FCC&amp;rsquo;s definition of &amp;ldquo;online marketplace&amp;rdquo; is limited to websites that accommodate third-party sellers, the Order seems to apply the rules both to entities that sell products directly to customers and to online marketplaces that provide a platform for third-party sellers. &lt;/p&gt;
&lt;p&gt;For listings subject to the rule, the specific requirements depend on the marketplace&amp;rsquo;s role in the transaction. Notably, if the marketplace sells the device itself, takes title to a third party&amp;rsquo;s device, or has physical access to the device through warehousing, fulfillment, consignment or shipping, the Order requires display of an FCC ID that is both valid and accurate for the listed product. If, however, a marketplace hosts a third-party listing but does not take title to or have physical access to the device, the marketplace must display a valid FCC ID, take reasonable steps to confirm that the ID is valid in the FCC&amp;rsquo;s database, and require the seller to certify the accuracy of the information. Marketplace operators are not required to provide FCC IDs for products sold by third-party sellers that are not &amp;ldquo;high-volume third-party sellers&amp;rdquo; or for listings for used devices. These new rules take effect six months after Federal Register publication for marketplaces that sell, take title to or physically handle devices, and nine months after publication for qualifying third-party listings where the marketplace does not take title.&lt;/p&gt;
&lt;h3&gt;Modifications to equipment manufactured by Covered List entities&lt;/h3&gt;
&lt;p&gt;The FCC adopted new restrictions on modifications to authorized equipment manufactured by Covered List entities. Going forward, any modification or permissive change performed by a Covered List entity must undergo full FCC certification, even if the underlying product was authorized through the Supplier&amp;rsquo;s Declaration of Conformity (SDoC) process, which covers products that emit radio waves but do not communicate with other devices. In addition, previously authorized equipment cannot later be modified in a manner that causes it to become covered equipment.&lt;/p&gt;
&lt;h3&gt;FCC considering additional changes&lt;/h3&gt;
&lt;p&gt;The Further Notice of Proposed Rulemaking signals additional changes that may be on the horizon. Among other proposals, the FCC seeks comment on requiring hardware and software bills of materials to be provided with equipment applications, expanding component restrictions to software and firmware, requiring certification for additional categories of devices, strengthening import restrictions, establishing expiration dates for equipment authorizations, and codifying permanent exceptions allowing software and firmware updates for previously authorized covered equipment in certain circumstances. These developments continue to reflect the FCC&amp;rsquo;s shift toward regulating the full communications equipment supply chain rather than focusing solely on finished products. The FCC also seeks comment on whether it should expand the rules to require online marketplaces to collect, verify or display information related to approvals through the SDoC.&lt;/p&gt;
&lt;p&gt;Companies involved in the design, manufacture or sale of FCC-regulated equipment should evaluate whether their existing compliance programs adequately address the FCC's expanding supply chain requirements. Companies that will be affected should consider filing comments, as many of the FCC&amp;rsquo;s proposals could expand compliance obligations for both manufacturers and retailers. &lt;/p&gt;
&lt;p&gt;If you have any questions about the Order or how it may impact your company, please contact the following Cooley communications attorneys:&lt;/p&gt;</description><pubDate>Wed, 29 Jul 2026 07:00:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{95ABEBAD-E6A3-49ED-9C20-CEC98F9DB6BA}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-28-align-ventures-closes-oversubscribed-$125-million-fund-ii</link><title>Align Ventures Closes Oversubscribed $125 Million Fund II</title><description>&lt;p&gt;&lt;strong&gt;Palo Alto &amp;ndash; July 28, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised Align Ventures, a venture capital firm investing in consumer brands and technologies, on the close of its &lt;a rel="noopener noreferrer" href="https://www.businesswire.com/news/home/20260727354033/en/Align-Ventures-Closes-Oversubscribed-%24125M-Fund-II" target="_blank"&gt;oversubscribed $125 million Early-Stage Fund II&lt;/a&gt;, which surpassed its $100 million target and brought the total platform's AUM to more than $2.5 billion as of June 2026.&lt;/p&gt;
&lt;p&gt;Lawyers John Clendenin, Dave Selden, Dave Young, Werner van der Westhuizen, Randy Coffey, James Allen, Stephanie Gentile, Maricel Mojares-Moore, Leila Kazerouni and Gabby Renauld led the Cooley team advising Align Ventures, with support from Margaret Barreto, Rebecca Evanson, Bernard Hatcher, Anya Krystal Castillo and Chris Rhem.&lt;/p&gt;
&lt;p&gt;Cooley previously advised Align Ventures on its participation in &lt;a href="https://www.cooley.com/news/coverage/2026/2026-05-21-align-ventures-invests-in-harks-$700-million-series-a"&gt;Hark&amp;rsquo;s $700 Million Series A&lt;/a&gt; in May 2026, its investment in &lt;a href="https://www.cooley.com/news/coverage/2026/2026-04-29-align-ventures-invests-in-scout-ais-oversubscribed-100-million-series-a"&gt;Scout AI&amp;rsquo;s oversubscribed $100 million Series A&lt;/a&gt; in April 2026, in &lt;a href="https://www.cooley.com/news/coverage/2025/2025-12-17-align-ventures-invests-in-radiants-oversubscribed-$300-million-series-d"&gt;Radiant&amp;rsquo;s oversubscribed $300 million+ Series D&lt;/a&gt; in December 2025, in &lt;a href="https://www.cooley.com/news/coverage/2025/2025-09-16-align-ventures-invests-in-figure-$1-billion-series-c-financing"&gt;Figure's $1 billion+ Series C&lt;/a&gt; in September 2025 and &lt;a href="https://www.cooley.com/news/coverage/2024/2024-02-29-align-ventures-invests-in-figure-ais-675-million-series-b"&gt;Figure&amp;rsquo;s $675 million Series B&lt;/a&gt; in February 2024.&lt;/p&gt;</description><pubDate>Tue, 28 Jul 2026 20:35:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{C99B483E-2DF8-4534-8518-2CF4D82D4930}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-28-cooley-grows-emerging-companies-and-venture-capital-practice-with-new-palo-alto-partner</link><title>Cooley Grows Emerging Companies and Venture Capital Practice With New Palo Alto Partner</title><description>&lt;p&gt;&lt;strong&gt;Palo Alto, CA – July 28, 2026 –&lt;/strong&gt; Frances Mosley has joined Cooley’s Palo Alto office as a partner in the emerging companies and venture capital (ECVC) practice, reinforcing the firm’s continued growth and investment in this core market.&lt;/p&gt;
&lt;p&gt;Mosley brings deep experience advising emerging companies across every stage of their business life cycle. Her practice is particularly focused on the medical device, digital health and life sciences sectors, complemented by a robust portfolio of work with AI and tech-driven ventures. A Silicon Valley native with nearly two decades of experience in the ECVC space, Mosley has advised many startups and investors from formation through exit.&lt;/p&gt;
&lt;p&gt;“We are incredibly excited to welcome Frances to our team,” said Peter Werner, Cooley partner, chair of the firm’s global business department and co-chair of the firm’s global emerging companies and venture capital practice group. “Frances’ focus on life sciences, digital health and tech, and her experience representing companies and investors, deepens our core strengths and capabilities in a critical market.”&lt;/p&gt;
&lt;p&gt;Mosley joins Cooley from DLA Piper, where she served as a partner representing tech and life sciences emerging growth companies and venture investors in general corporate matters, board governance, securities law compliance, venture capital, debt financing and M&amp;amp;A.&lt;/p&gt;
&lt;p&gt;“Frances’ arrival to the firm’s Palo Alto office reflects Cooley’s continued commitment to being the best law firm for life sciences, digital health and tech companies in this core market,” said Erik Edwards, partner and head of Cooley’s Palo Alto corporate group. “Frances’ addition builds on that commitment and reinforces our position as the partner of choice for private companies in Silicon Valley.”&lt;/p&gt;
&lt;p&gt;“I am thrilled to join Cooley’s world-class ECVC platform,” said Mosley. “Cooley’s deep roots in the emerging companies and venture capital space make it the ideal home for my practice and clients, wherever they may be in their life cycle. I look forward to supporting entrepreneurs and investors alike alongside a team that is laser-focused on helping innovative companies succeed at the highest levels.”&lt;/p&gt;
&lt;p&gt;Cooley is the go-to advisor to innovators and disruptors. As one of the most active firms globally in advising on early- and late-stage financings, initial public offerings and M&amp;amp;A, Cooley combines a multidisciplinary platform with efficient, tech-enabled resources designed to provide clients with premium counsel through each stage as they scale. Cooley is deeply connected in the venture ecosystem, working with startups, boards, management teams and investors to support 7,000+ high-growth private companies reshaping the global economy.&lt;/p&gt;</description><pubDate>Tue, 28 Jul 2026 20:34:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{FCB5AA69-B9ED-4B79-A289-8364C4D47737}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-28-cooley-shortlisted-across-multiple-categories-in-asia-legal-awards</link><title>Cooley Shortlisted Across Multiple Categories in Asia Legal Awards</title><description>&lt;p&gt;&lt;strong&gt;Singapore &amp;ndash; July 28, 2026&lt;/strong&gt;&amp;nbsp;&lt;strong&gt;&amp;ndash;&lt;/strong&gt; Cooley has been shortlisted in four categories in Law.com International&amp;rsquo;s The Asia Legal Awards 2026, which recognize the region&amp;rsquo;s most outstanding legal achievements.&lt;/p&gt;
&lt;p&gt;The firm was shortlisted in one practice category, one individual category and two deal categories:&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;Investment Funds Firm of the Year&lt;/li&gt;
    &lt;li&gt;IPO Lawyer of the Year: Partner &lt;a href="https://www.cooley.com/people/michael-yu"&gt;Michael Yu&lt;/a&gt;&lt;/li&gt;
    &lt;li&gt;M&amp;amp;A Deal of the Year: &lt;a href="https://www.cooley.com/news/coverage/2025/2025-07-25-inmagene-biopharmaceuticals-completes-merger-with-ikena-oncology-updated"&gt;Inmagene Biopharmaceuticals&amp;rsquo; merger with Ikena Oncology&lt;/a&gt;&lt;/li&gt;
    &lt;li&gt;Securities Deal of the Year: Equity: For its representation of &lt;a href="https://www.cooley.com/news/coverage/2025/2025-11-05-seres-announces-hk$14-28-billion-ipo"&gt;the underwriters of Seres Group in the company&amp;rsquo;s HK$14.28 billion (US$1.7 billion) initial public offering (IPO) &lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;This marks the second consecutive year that Cooley has been shortlisted for Investment Funds Firm of the Year and Michael Yu has been shortlisted for IPO Lawyer of the Year.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.event.law.com/asialegalawards/2026-shortlist" target="_blank"&gt;View the full shortlist&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;An awards ceremony will be held in Singapore on September 10.&lt;/p&gt;</description><pubDate>Tue, 28 Jul 2026 15:04:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{9A9C9538-0596-4244-BAE1-51426D4B842F}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-27-research-alliance-corporation-iii-to-combine-with-oak-hill-bio</link><title>Research Alliance Corporation III to Combine with Oak Hill Bio</title><description>&lt;p&gt;Cooley advised Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, on its definitive business combination agreement with Oak Hill Bio to create a publicly listed rare disease biotechnology company to advance antisense oligonucleotide therapy rugonersen for Angelman syndrome. The transaction will to provide Oak Hill Bio with approximately $175 million in gross proceeds, including $75 million of cash in RACC&amp;rsquo;s trust account that is fully backstopped by RA Capital Management and a $100 million committed private financing. Upon consummation of the transaction, which is expected to close by year-end 2026 subject to customary closing conditions, Oak Hill Bio shares of common stock will be listed on the Nasdaq Capital Market under the ticker symbol &amp;ldquo;OAKH&amp;rdquo;.&lt;/p&gt;
&lt;p&gt;The transaction was announced publicly in the following press release, which can be viewed&amp;nbsp;&lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/07/27/3333485/0/en/oak-hill-bio-and-research-alliance-corporation-iii-announce-business-combination-agreement-to-create-publicly-listed-rare-disease-biotechnology-company-to-advance-antisense-oligonu.html?_gl=1*1vc3bwt*_up*MQ..*_ga*MTUzNDczNjA5OC4xNzg1MTU1Nzg4*_ga_B6167QB2TF*czE3ODUxNTU3ODckbzEkZzAkdDE3ODUxNTU3ODckajYwJGwwJGgxOTE3MjU5OTA0*_ga_ERWPGTJ5X8*czE3ODUxNTU3ODgkbzEkZzAkdDE3ODUxNTU3ODgkajYwJGwwJGgw" target="_blank"&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Eric Blanchard, Kevin Cooper, Lindsey O&amp;rsquo;Crump, James Schneider, Mike Nelson and Susan Choy led the Cooley team advising RACC.&lt;/p&gt;
&lt;p&gt;Russell Anderson, Kafeel Azher, Nitasha Bennett, Michael Bergmann, Chelsea Braun, Matt Choy, Raphael Davidian, Alison Freeman-Gleason, Dillon Jones, Jack Jones, Angela Kim, Eileen Leman, Madhur&lt;span style="letter-spacing: 0.48px;"&gt;i Roy, Emily Mok, Aaron Pomeroy, Gregg Rader, Sanjay Reddy, Nicola Squire, Chris Stack, David Wilson, Noah Wyle Goldman, and Joanna Zhang provided invaluable support.&lt;/span&gt;&lt;/p&gt;</description><pubDate>Mon, 27 Jul 2026 19:19:36 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{877EC24B-C45D-4FD5-8582-CCC8B1475040}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-27-the-evolving-adtech-landscape</link><title>The Evolving Adtech Landscape</title><description>&lt;p&gt;Cooley lawyers Meredith Halama, Katie Cramer and Claire Gibbs were quoted in a Cybersecurity and AI Law Report article about recent developments in adtech law, examining how evolving privacy laws and increased enforcement are affecting companies that rely on consumer data.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.cslawreport.com/21476566/the-evolving-adtech-landscape.thtml" target="_blank"&gt;Read the article (subscription required)&lt;/a&gt;&lt;/p&gt;</description><pubDate>Mon, 27 Jul 2026 18:10:22 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{605372BC-357F-432F-AE05-098D1FC574BC}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-24-am-law-100-associates-are-on-the-front-lines-of-legal-ai-experimentation</link><title>Am Law 100 Associates Are on the Front Lines of Legal AI Experimentation</title><description>&lt;p&gt;Matthew Bartus, partner and global co-chair of Cooley&amp;rsquo;s emerging companies and venture capital practice group, was quoted in Law.com about the firm&amp;rsquo;s use of AI among lawyers and administrative staff.&lt;/p&gt;
&lt;p&gt;&lt;a rel="noopener noreferrer" href="https://www.law.com/americanlawyer/2026/07/24/am-law-100-associates-are-on-the-front-lines-of-legal-ai-experimentation/" target="_blank"&gt;Read the article (subscription required)&lt;/a&gt;&lt;/p&gt;</description><pubDate>Fri, 24 Jul 2026 19:31:56 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{F15F84B7-6FE4-49F9-91E9-0325BA1A3CC6}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-23-copra-acquired-by-the-vita-coco-company</link><title>Copra Acquired by The Vita Coco Company</title><description>&lt;p&gt;Cooley advised Copra, one of the leading producers of super-premium Thai Nam Hom coconut water, on its acquisition by The Vita Coco Company, a leading high-growth platform of better-for-you beverage brands.&lt;/p&gt;
&lt;p&gt;The purchase price consisted of an upfront consideration of $175 million paid at closing, subject to customary closing adjustments, with additional earnout consideration to be paid in 2029 based on 2028 financial performance with a floor of $45 million and a cap of $100 million. The initial purchase price consisted of 80% cash on hand with the balance paid in Vita Coco common stock.&lt;/p&gt;
&lt;p&gt;The transaction was announced publicly in the following press release, which can be viewed &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/07/22/3331759/0/en/The-Vita-Coco-Company-Announces-the-Acquisition-of-Copra-Inc.html" target="_blank"&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Kester Spindler, Mystery Murphy, Nick Cagle and Josh Morris led the Cooley team advising Copra.&lt;/p&gt;</description><pubDate>Thu, 23 Jul 2026 20:09:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{EFD7B457-9BB9-4DED-8A81-CEAA4EA9A9ED}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-23-savano-capital-partners-closes-oversubscribed-$252-million-fund-iv</link><title>Savano Capital Partners Closes Oversubscribed $252 Million Fund IV</title><description>&lt;p&gt;&lt;strong&gt;Chicago &amp;ndash; July 23, 2026 &amp;ndash; &lt;/strong&gt;Cooley advised Savano Capital Partners ("Savano"), a direct secondary investment firm focused on mature, high-growth software and technology companies, &lt;a rel="noopener noreferrer" href="https://www.prnewswire.com/news-releases/savano-capital-partners-closes-oversubscribed-252-million-fund-iv-302832444.html" target="_blank"&gt;on the final close of Savano Capital Partners IV, L.P. ("Fund IV")&lt;/a&gt; with $252 million in capital commitments, exceeding its target. Fund IV is the largest fund in Savano's history and brings total capital commitments across the firm's funds and co-investment vehicles since inception to more than $600 million.&lt;/p&gt;
&lt;p&gt;Lawyers Rachel Goddard, Katia MacNeill and Chris Bates led the Cooley team advising Savano.&lt;/p&gt;</description><pubDate>Thu, 23 Jul 2026 18:17:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{6DF80C1F-7146-4886-827C-B9FB5F1973BC}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-23-scancell-to-acquire-neuphoria-concurrent-$89-million-private-financing</link><title>Scancell to Acquire Neuphoria, Concurrent $89 Million Private Financing</title><description>&lt;p&gt;Cooley advised Scancell, a late-stage clinical biotechnology company, on its agreement to acquire Neuphoria Therapeutics, a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Upon completion of the transaction, the combined company plans to operate under the name Scancell and will apply to trade on Nasdaq under the symbol &amp;ldquo;SCLT&amp;rdquo;.&lt;/p&gt;
&lt;p&gt;In connection with the transaction, Cooley also advised Scancell on a concurrent private financing of $89 million through a combination of equity and debt.&lt;/p&gt;
&lt;p&gt;The transaction was announced publicly in the following press release, which can be viewed&amp;nbsp;&lt;a rel="noopener noreferrer" href="https://www.londonstockexchange.com/news-article/SCLP/merger-and-financing/17702418" target="_blank"&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Claire Keast-Butler, Rita Sobral, Russell Anderson, Courtney Thorne, Marc Recht, Katherine Denby, Reid Hooper, Susan Choy, Wouter Deleersnyder, Sydney Sawyier and Philip Whitehead led the Cooley team advising Scancell.&lt;/p&gt;
&lt;p&gt;Jack Jones, David Wilson, Joe Sandys, Bilal Ahmadzai, Arthur Courroy, Olivia Creser, Joshua Cronin, Navya Dasari, Alexandra Paterson and Agnes Wong provided invaluable support.&lt;/p&gt;
&lt;p&gt;Cooley has advised Scancell for over a decade on various corporate matters, including public offerings and licensing agreements.&lt;/p&gt;</description><pubDate>Thu, 23 Jul 2026 17:34:17 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{E7F6985B-72FA-4769-8AD4-73200D3F2FD4}</guid><link>https://www.cooley.com/news/insight/2026/2026-07-23-cooley-submits-comments-on-dfpis-proposed-rulemaking-under-californias-vc-diversity-reporting-law</link><title>Cooley Submits Comments on DFPI’s Proposed Rulemaking Under California’s VC Diversity Reporting Law</title><description>&lt;p&gt;Cooley recently submitted a &lt;a href="-/media/aaf568c6f6a2468699464b5b7032de08.ashx"&gt;formal comment letter&lt;/a&gt;&amp;nbsp;to the California Department of Financial Protection and Innovation (DFPI), in response to the agency&amp;rsquo;s invitation for comments on &lt;a rel="noopener noreferrer" href="https://dfpi.ca.gov/wp-content/uploads/2026/05/PRO-01-26-FIPVCC-Invitation-for-Comments-5-19-2026.pdf" target="_blank"&gt;proposed rulemaking&lt;/a&gt;&amp;nbsp;under the Fair Investment Practices by Venture Capital Companies Law (FIPVCC).&lt;/p&gt;
&lt;p&gt;The letter urges the DFPI to use the rulemaking process to resolve critical ambiguities in the FIPVCC and establish a workable compliance framework for the venture capital industry. Key recommendations include narrowing the &amp;ldquo;covered entity&amp;rdquo; definition with clear nexus standards, permitting consolidated reporting by controlling entities to reduce duplicative obligations, limiting the scope of reportable investments, excluding foreign investments from surveying and reporting obligations, allowing use of third-party platforms and substantively equivalent survey and reporting forms, and strengthening confidentiality and anonymization protections for firms and founders&lt;em&gt;.&lt;/em&gt; These comments build on a &lt;a href="https://www.cooley.com/news/insight/2026/2026-03-18-dfpi-suspends-implementation-enforcement-of-californias-vc-companies-diversity-reporting-program-pending-rulemaking"&gt;March 2026 letter&lt;/a&gt; in which Cooley separately requested regulatory guidance on consolidated reporting, registration obligations and the scope of the survey distribution requirement.&lt;/p&gt;
&lt;p&gt;Cooley also recommended that the DFPI maintain its current suspension of implementation and enforcement until the pending constitutional challenge filed in the US District Court for the Eastern District of California (&lt;em&gt;1517 Management Company, LLC, et al. v. Mohseni&lt;/em&gt;, No. 2:26-cv-01957) is resolved. Following Cooley&amp;rsquo;s submission, the parties filed (and the court granted) a joint stipulation to extend the response deadline to July 31, 2026, to allow time for an anticipated joint motion to stay all deadlines and proceedings in the litigation, pending the DFPI&amp;rsquo;s issuance of final rules.&lt;/p&gt;
&lt;p&gt;Cooley will continue to monitor the rulemaking, engage with the DFPI on behalf of our clients and assist clients in assessing their obligations under the FIPVCC.&lt;/p&gt;</description><pubDate>Thu, 23 Jul 2026 16:35:05 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{71CEC9F6-B5AC-4519-BC94-34EF3A2C2866}</guid><link>https://www.cooley.com/news/insight/2026/2026-07-21-from-opt-in-to-opt-out-sec-proposes-electronic-delivery-as-default-for-required-disclosures</link><title>From Opt In to Opt Out: SEC Proposes Electronic Delivery as Default for Required Disclosures</title><description>&lt;p&gt;On July 16, 2026, the Securities and Exchange Commission (SEC) voted to propose &lt;a rel="noopener noreferrer" href="https://www.sec.gov/files/rules/proposed/2026/33-11430.pdf" target="_blank"&gt;Regulation E-Delivery&lt;/a&gt;, a sweeping new framework that would make electronic delivery the default method for satisfying required disclosure delivery obligations under the federal securities laws. Under the proposal, covered entities, including issuers, broker-dealers, investment advisers, investment companies and other market participants, could deliver regulatory documents electronically without first obtaining each recipient&amp;rsquo;s affirmative consent. This marks a fundamental shift from the current framework, which has required investors and other recipients to opt in for electronic delivery and has otherwise defaulted to paper.&lt;/p&gt;
&lt;h3&gt;New default electronic delivery framework&lt;/h3&gt;
&lt;p&gt;The proposal would replace the SEC&amp;rsquo;s decades-old, guidance-based approach with a uniform rule establishing clear conditions for default electronic delivery. A covered entity could rely on Regulation E-Delivery where:&lt;/p&gt;
&lt;ol&gt;
    &lt;li&gt;The recipient has provided an electronic address.&lt;/li&gt;
    &lt;li&gt;The entity has given the recipient prominent advance disclosure that covered information will be sent electronically.&lt;/li&gt;
    &lt;li&gt;The recipient has not opted out.&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;Importantly, Regulation E-Delivery is not a blanket rule. It would permit but not require electronic delivery. A covered entity may rely on it only where those conditions are satisfied, and it does not permit a blanket shift of all investors and other recipients to electronic delivery regardless of circumstances.&lt;/p&gt;
&lt;h4&gt;Methods of electronic delivery&lt;/h4&gt;
&lt;p&gt;The proposal provides two permissible methods of electronic delivery. For covered information that does not include personal financial information, a covered entity may deliver materials directly to the recipient&amp;rsquo;s electronic address; for example, as an email attachment or embedded document. For covered information that does include personal financial information, however, direct delivery is not permitted; instead, the covered entity must send a statement of availability directing the recipient to a secure website where the materials can be accessed. Covered entities may also elect to use the statement of availability method for materials that do not contain personal financial information.&lt;/p&gt;
&lt;h4&gt;Key investor protections&lt;/h4&gt;
&lt;p&gt;Covered recipients would retain the right to receive paper copies free of charge at any time. Investors currently receiving paper communications would receive two paper transition notices before being moved to electronic delivery, an initial notice at least 180 days before the transition and a follow-up notice approximately 30 days before.&lt;/p&gt;
&lt;h4&gt;Transition period&lt;/h4&gt;
&lt;p&gt;If adopted, the rule&amp;rsquo;s effective date would be 60 days after publication of the final rule in the Federal Register, with a two-year transition period before the current guidance-based framework is rescinded. The comment period will be open for 60 days following publication of the proposing release in the Federal Register, with comments due on or before September 21, 2026. The SEC has invited comment on several implementation aspects of the proposal, including the transition timeline, the mechanics of paper notice requirements and the framework&amp;rsquo;s treatment of recipients who prefer to continue receiving paper materials.&lt;/p&gt;
&lt;h3&gt;Impact on proxy season&lt;/h3&gt;
&lt;p&gt;For public companies, the proposal&amp;rsquo;s most immediate practical impact falls on the annual proxy process. Transitions to default electronic delivery of proxy statements and annual meeting materials could meaningfully reduce printing and mailing costs and lessen the administrative burden associated with annual meeting preparation.&lt;/p&gt;
&lt;h4&gt;Current delivery framework&lt;/h4&gt;
&lt;p&gt;Currently, issuers may satisfy proxy delivery obligations either by mailing a full set of proxy materials (on paper or electronically, for shareholders who previously opted in) or by using the SEC&amp;rsquo;s notice-and-access model, under which shareholders receive a paper Notice of Internet Availability directing them to proxy materials posted online.&lt;/p&gt;
&lt;h4&gt;Replacing the paper notice&lt;/h4&gt;
&lt;p&gt;The proposal would eliminate the paper Notice of Internet Availability as a stand-alone delivery method. In its place, shareholders with an electronic address who have not opted out would receive an electronic statement of availability, delivered to their electronic address and including a direct link to the proxy materials posted online. Shareholders would retain the right to opt out and receive a full paper set of materials at any time.&lt;/p&gt;
&lt;h4&gt;Related amendments to Exchange Act Rule 14a-16&lt;/h4&gt;
&lt;p&gt;The proposed changes to Rule 14a-16 under the Securities Exchange Act of 1934, as amended (Exchange Act), would also eliminate the long-standing 40-calendar-day e-proxy deadline. Because that deadline was specifically designed to give shareholders sufficient time to receive the paper notice, request paper copies of the materials, if desired, and review the proxy materials prior to executing a proxy, its removal follows naturally from the elimination of the paper notice itself. The proposal would also extend the electronic delivery framework to business combination proxy solicitations, which have historically required delivery of a full paper set of materials.&lt;/p&gt;
&lt;h3&gt;Additional amendments&lt;/h3&gt;
&lt;p&gt;In addition to establishing the new default delivery framework, the proposal would rescind Rule 30e-3 under the Investment Company Act, which currently provides registered investment companies with an alternative means to satisfy shareholder report transmission requirements. The proposal would also amend the rules governing the dissemination of tender offer materials in Rule 14d-5 under the Exchange Act. The SEC has noted that the proposal is intended to reduce unnecessary printing and mailing costs while providing investors with more timely, accessible and interactive disclosures that better reflect current communication practices.&lt;/p&gt;
&lt;p&gt;***&lt;/p&gt;
&lt;p&gt;Regulation E-Delivery is part of a broader pattern in the SEC&amp;rsquo;s current regulatory agenda: revisiting existing rules and guidance to give issuers and market participants greater flexibility to disclose and disseminate material information in real time, while maintaining the investor protection principles that underpin the existing federal securities framework.&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;
&lt;p&gt;Cooley&amp;rsquo;s corporate governance and securities regulation attorneys are available to discuss these issues with you.&lt;/p&gt;
&lt;h5&gt;Notes&lt;/h5&gt;
&lt;ol&gt;
    &lt;li&gt;This approach is further illustrated by two Corporation Finance Interpretations issued by the SEC&amp;rsquo;s Division of Corporation Finance in July 2026 (&lt;a rel="noopener noreferrer" href="https://urldefense.com/v3/__https://www.sec.gov/rules-regulations/staff-guidance/corporation-finance-interpretations/tender-offer-rules-schedules*104.03__;Iw!!OPvj_Mo!-i99Mny-BfM-GvvIz7W7Iwca9dlT1sIQyBd2afy8Xwpumpd07Dp_hlfKQHglH1s649E6MwrU-KB3DcxvJKSBOdAHD5k$" target="_blank"&gt;CFIs 104.03&lt;/a&gt; and &lt;a href="https://urldefense.com/v3/__https://www.sec.gov/rules-regulations/staff-guidance/corporation-finance-interpretations/tender-offer-rules-schedules*131.04__;Iw!!OPvj_Mo!-i99Mny-BfM-GvvIz7W7Iwca9dlT1sIQyBd2afy8Xwpumpd07Dp_hlfKQHglH1s649E6MwrU-KB3DcxvJKSB-TvTo8U$"&gt;131.04&lt;/a&gt;), which expanded the methods available to bidders for disseminating tender offer materials at commencement. Under the updated guidance, bidders in all-cash and exempt securities issuer and third-party tender offers that are not going-private transactions may satisfy the commencement dissemination requirement by issuing a press release through a widely disseminated news or wire service that contains a hyperlink to the full offer materials, in lieu of a summary newspaper advertisement or a mailing to shareholders. A bidder relying on this method must still mail by first-class mail, or otherwise furnish with reasonable promptness, its offer materials to any shareholder who requests them.
    &lt;/li&gt;
&lt;/ol&gt;</description><pubDate>Wed, 22 Jul 2026 21:50:00 Z</pubDate><a10:content type="html" /></item><item><guid isPermaLink="false">{183B0562-4F50-4212-ACDA-740DB45B082E}</guid><link>https://www.cooley.com/news/coverage/2026/2026-07-22-glow-emerges-from-stealth-with-$180-million</link><title>Glow Emerges From Stealth With $180 Million</title><description>&lt;p&gt;&lt;strong&gt;New York &amp;ndash; July 22, 2026 &amp;ndash;&lt;/strong&gt; Cooley advised Redpoint Ventures, a venture capital firm investing in startups across the seed, early and growth phases, as a lead investor in &lt;a rel="noopener noreferrer" href="https://www.globenewswire.com/news-release/2026/07/22/3331154/0/en/glow-emerges-from-stealth-with-180-million-to-reinvent-endpoint-security-in-the-ai-era.html" target="_blank"&gt;Glow&amp;rsquo;s $180 million funding round&lt;/a&gt;, at a $1.2 billion valuation. The round was also led by Sequoia, Cyberstarts and Greenoaks, with additional participation from Index Ventures, Swish Ventures, Lux Capital, Operator Collective and Holly Ventures.&lt;/p&gt;
&lt;p&gt;Lawyers Andrew Gunther and Chris Chynoweth led the Cooley team advising Redpoint Ventures.&lt;/p&gt;</description><pubDate>Wed, 22 Jul 2026 20:21:00 Z</pubDate><a10:content type="html" /></item></channel></rss>